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The Role of Aryl Hydrocarbon Receptor in
Blood Pressure Regulation and Vascular Homeostasis

By

Nan Zhang
B.S., Biological Sciences, Fudan University, 2003
Ph.D., Biomedical Sciences, University of New Mexico, 2009

ABSTRACT

High blood pressure and endothelial dysfunction are two systemic abnormalities
of the cardiovascular system that extensively contribute to the etiology of cardiovascular
diseases, which represent the number one killer in the United States for decades and
become more severe in developing countries. Previous studies have indicated that aryl
hydrocarbon receptor (AHR), a transcription factor primarily mediating xenobiotic
metabolism, plays an important role in cardiovascular development and physiology.
AHR deficient mice have been demonstrated to develop hypotension at sea level and
oxygen-dependent, endothelin-1 (ET-1) mediated hypertension at mild altitude.
However, after generations at mild altitude, AHR deficient mice appear to acclimate to
the lower atmospheric partial pressure of oxygen and exhibit normal levels of ET-1 and
hypotension. Therefore, the goal of my research was to elucidate the mechanism by
which endogenous AHR regulates blood pressure by studying blood pressure regulation
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in the absence of the AHR. I found that AHR deficient mice exhibit significantly lower
systemic arterial blood pressure, dysregulated circadian blood pressure rhythm, and
significantly elevated vascular endothelial nitric oxide synthase (eNOS) expression and
systemic production of nitric oxide (NO). I found that treating AHR deficient mice with
the NOS inhibitor, Nω-nitro-L-arginine (LNNA) failed to normalize blood pressure,
suggesting that vascular eNOS over expression may not be the primary mediating factor
of hypotension in AHR knockout mice. Further investigation on vascular activity ex vivo
indicated increased sensitivity of vascular smooth muscle to NO which may
simultaneously contribute to the hypotension in this scenario. In vitro studies using
human aortic endothelial cells with AHR expression knockdown by siRNA suggested an
intracellular role of endogenous AHR signaling in suppressing eNOS mRNA expression,
which could be normalized by exogenous ligand activation of the residual AHR. My
results suggest that AHR suppresses eNOS expression and acts to maintain basal vascular
tone and normal blood pressure. Therefore, therapeutic approaches that antagonize AHR
signaling could improve NO bioavailability and benefit patients with hypertension and
vascular diseases commonly associated with endothelial dysfunction.
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CHAPTER I
INTRODUCTION
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CARDIOVASCULAR DISEASES
Cardiovascular diseases are a group of disorders of the heart and blood vessels,
including high blood pressure, coronary heart disease, stroke, and heart failure.
Cardiovascular diseases are the number one killer in the United States, and about one
third (80 million) of adults have one or more types of cardiovascular diseases nowadays
(Lloyd-Jones, D. et al. 2009). The etiology of cardiovascular diseases is multifactorial
and involves both genetic factors, such as family history, and environmental factors, such
as high fat diet and tobacco use.

BLOOD PRESSURE ALTERATION IN CARDIOVASCULAR DISEASES
Blood pressure reflects the work intensity of cardiovascular system. It needs to be
maintained at certain level to supply sufficient oxygen and nutrients and to remove
metabolic by-products from each organ, especially the brain and heart. The effect of high
blood pressure on the vascular wall dramatically promotes the development of
atherosclerosis, and subsequently myocardial infarction and stroke, two types of
cardiovascular diseases with the highest morbidity and mortality. Statistically, of the 80
million people who have at least one type of cardiovascular disease in the U.S., 73.6
million (92%) have hypertension, which is defined as systolic blood pressure ≥ 140 mm
Hg and/or diastolic blood pressure ≥ 90 mm Hg (Lloyd-Jones, D. et al. 2009).
Unfortunately, the etiology of 90% of the cases of hypertension is unknown.
In contrast to hypertension, hypotension, a systolic blood pressure ≤ 90 mm Hg
and/or diastolic blood pressure ≤ 60 mm Hg (National Heart Lung and Blood Institute,
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Diseases and Conditions Index, 2008), can deprive the brain and other vital organs of
oxygen and nutrients, leading to a life-threatening condition called shock. Hypovolemia,
resulting from severe hemorrhage or dehydration, is recognized as the most common
cause of hypotension and shock. Hypotension also can be cardiogenic and caused by
myocardial infarction and heart arrhythmias through decreasing cardiac output (Guyton,
A.C. and Hall, J.E. 2006; Holmes, D.R., Jr. 2003). It also can be neurogenic, in which
low blood pressure is caused by excessive vasodilation derived from abnormal autonomic
nerve output after brain or spinal cord injury (Guyton, A.C. and Hall, J.E. 2006). In
addition to loss of autonomic output, sepsis and severe systemic allergic reactions are two
other conditions that induce marked vasodilation, thus hypotension and shock (Guyton,
A.C. and Hall, J.E. 2006; Cauwels, A. 2007). These two types of shock are called septic
shock and anaphylactic shock. Epidemiology studies indicate that the incidence of septic
shock is growing by 9% per year (Annane, D. et al. 2005; Martin, G.S. et al. 2003) with
an extremely high mortality rate of 50-70%. The frequency of anaphylaxis is also
increasing due to the increased incidence of allergies and potential allergens to which
people are exposed (Cauwels, A. 2007).
BLOOD PRESSURE REGULATION
Mean arterial blood pressure (MAP) is determined by cardiac output (CO),
systemic vascular resistance (SVR) and central venous pressure (CVP) according to the
following relationship:
MAP = CO × SVR + CVP
Because CVP is usually at or near 0 mm Hg, this relationship is often simplified to:
3

MAP = CO × SVR
Therefore, MAP could be affected by changes in either CO or SVR, which are
normally independent variables. SVR can be calculated by SVR = MAP ÷ CO, but
not determined by either MAP or CO. Cardiac output is determined by stroke volume
(SV) and heart rate (HR), thus MAP can be expressed as:

MAP = SV × HR × SVR
Arterial blood pressure is continuously monitored by various sensors located
within the body and regulated through adjustments in cardiac output and systemic
vascular resistance when it varies from the normal value. In the short term, the
arterial baroreceptor reflex is the primary regulatory mechanism. Arterial
baroreceptors are predominantly located at the aortic arch and carotid arteries. The
action potential of the receptors changes in response to the degree of stretch on
vascular wall caused by blood pressure alteration, and travels to the medullary
cardiovascular center for integration. Integrated feedback is sent through sympathetic
and parasympathetic nerves to the heart and vasculature to regulate vascular tone,
heart rate and stroke volume, and thus blood pressure (Figure 1). In the long term,
baroreceptor firing rate adapts to prolonged changes in arterial pressure.
Chronic regulation of blood pressure is subjected to the glomerular filtration
rate and renal fluid reabsorption, which is controlled by the renin-angiotensin system
(RAS). Herein the affected parameters in determining blood pressure are CO (blood
volume, precisely) and vascular resistance (by angiotensin II, Figure 2).
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Figure 1. Arterial baroreceptor reflex pathway (Mohrman, D.E. and Heller, L.J.
2006). MAP, mean arterial blood pressure; CO, cardiac output; SVR, systemic
vascular resistance; SV, stroke volume; HR, heart rate.
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Figure 2. Mechanisms by which arterial pressure influences urinary output rate
(revised from Mohrman, D.E. and Heller, L.J. 2006). MAP, mean arterial blood
pressure; CO, cardiac output; SVR, systemic vascular resistance.
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Vascular resistance. It is also well established that regulation of vascular
resistance plays an important role in blood pressure control under both normal and
pathological conditions.
Small muscular arteries and arterioles are the primary vessels that generate
systemic vascular resistance (50-70%, Klabunde, R.E. 2004). The resistance (R) of a
segment of vessel is determined by Poiseuille’s Equation:

η = viscosity of the blood, L = length of vessel and r = radius of vessel
From this equation, we can see that a 2 fold decrease in vessel radius would cause a
16 fold increase in vascular resistance. Since length and viscosity of the blood is
usually consistent, the vessel radius becomes the primary driving force in systemic
vascular resistance.
All small muscular arteries and arterioles basally exhibit a certain degree of
smooth muscle contraction that determines the diameter, and hence the resistance. This
smooth muscle contraction, also known as vascular tone, is determined by the balance of
a number of competing vasoconstrictors and vasodilators. Those vasoconstrictors and
vasodilators fall into two categories (Klabunde, R.E. 2004), extrinsic factors:
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•

Neurohormones released from autonomic nerves, such as norepinephrine (NE,
vasoconstrictor) and acetylcholine (ACh, vasodilator) from sympathetic and
parasympathetic innervations, respectively.

•

Angiotensin II generated in RAS (vasoconstrictor).

•

Atrial natriuretic peptide (vasodilator).

and intrinsic factors:
•

Myogenic mechanisms (originating from vascular smooth muscle), which
increase tone.

•

Endothelial-derived vasodilatory factors, such as nitric oxide (NO), prostacyclin
(PGI2), endothelium-derived hyperpolarizing factor (EDHF), and vasoconstrictors,
such as endothelin.

•

Local hormones and chemical substances, such as arachidonic acid metabolites,
histamine and bradykinin.

•

Hypoxia.
Among all the tissues and organs involved in regulating vascular tone, the

endothelium attracts particular attention not only due to its role in endothelium-dependent
vasodilation, but also in immune and inflammatory reactions, both of which have
significant impact on cardiovascular diseases, such as hypertension and atherosclerosis.

ENDOTHELIUM
Endothelial cells form a single layer across the entire vascular system. An adult
has approximately 1013 endothelial cells (Galley, H.F. et al. 2004), with a comparable
8

weight to the liver. In addition to the function of maintaining vascular wall and
molecular transportation as a semi-permeable barrier, endothelial cells are dynamic and
have both metabolic and synthetic functions (Galley, H.F. et al. 2004). They synthesize
and secrete a number of factors that modulate vascular tone, angiogenesis and
inflammatory responses (Feletou, M. et al. 2006).
Endothelium in vascular tone regulation. Endothelium produces a pool of
vasoactive factors, together with other neurohormonal stimuli, to act on smooth muscle
cells to regulate vascular tone. NO, PGI2 and EDHF are the most important factors
produced by endothelium in relaxing the vasculature. In conduit vessels, endotheliumderived NO and PGI2 are the predominant factors in causing vasodilation, while in small
resistant vessels, EDHF tends to play a greater role in regulating vascular tone (Harrison,
D.G. et al. 2003; Scotland, R.S. et al. 2005).
Endothelial cells also produce endothelin-1 (ET-1), particularly in pathological
circumstances, to cause potent vasoconstriction. A number of receptors for paracrine and
endocrine agonists are also expressed on the surface of endothelial cells, and mediate the
release of endothelial-derived vasodilators. For instance, ET-1 can bind to its ETB
receptor on the endothelial cell surface to stimulate the release of NO (Hirata, Y. et al.
1993). In addition, angiotensin converting enzyme (ACE) is expressed on the surface of
endothelial cells and catalyzes production of angiotensin II, a strong vasoconstrictor.
NITRIC OXIDE
NO is a highly lipophilic and diffusible gas and contains a single oxygen atom
bonded to a nitrogen atom. It mediates diverse signaling pathways in multiple organ
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systems (Dudzinski, D.M. et al. 2006) and is crucial in maintaining endothelial function
to protect the cardiovascular system from pathologic damage.
NO as an endothelium-derived relaxing factor. In 1980, an endothelium-derived
relaxing factor (EDRF) was discovered by Furchgott and Zawadzki. They demonstrated
that ACh-induced vasodilation requires anatomical integrity of the endothelium
(Furchgott, R.F. et al. 1980). Seven years later, this EDRF was identified as NO (Ignarro,
L.J. et al. 1987). Nowadays, NO is one of the most well characterized vascular relaxing
factors generated primarily by endothelial nitric oxide synthase (eNOS) in vascular
endothelium. After being produced by endothelial cells, NO is transported into adjacent
vascular smooth muscle cells (VSMC) by aquaporin (Herrera, M. et al. 2006), and causes
VSMC relaxation through a variety of mechanisms, including decreasing intracellular
calcium, desensitizing the contractile apparatus to calcium, and hyperpolarizing the cell
membrane either directly or indirectly through cyclic guanosine monophosphate (cGMP)
as a second messenger (Figure 3). NO is also involved in other important vascular
functions, including leukocyte activation, platelet aggregation, interactions between the
endothelium and circulating cells, and VSMC proliferation (Huang, P.L. 2000).
NO synthesis. NO is synthesized from L-arginine by three isoforms of nitric
oxide synthases (NOS) in mammals: neuronal NOS, or nNOS (NOS I); inducible NOS,
or iNOS (NOS II); and endothelial NOS, or eNOS (NOS III). nNOS and eNOS are
predominantly expressed in nervous system and endothelium respectively, and iNOS is
induced under inflammatory conditions. Three NOS isoforms are products of distinct
genes but share 50-60% sequence identity and basic chemical properties (Dudzinski, D.M.
et al. 2006). Generally they catalyze the reaction to produce NO:
10

Figure 3. Vascular nitric oxide production and function on smooth muscle cells.
Vascular NO is generated from eNOS and other sources, such as mitochondria and
xanthine oxidase in endothelial cells. eNOS can be regulated at the transcriptional level,
through protein phosphorylation and by factors that affect intracellular calcium
concentration. NO causes relaxation of adjacent smooth muscle cells through variety of
pathways. TGF-β, transforming growth factor-β; ACh, acetylcholine; NO, nitric oxide;
eNOS, endothelial nitric oxide synthase; sGC, soluble guanylyl cyclase; GTP, guanosine
triphosphate; cGMP, cyclic guanosine monophosphate; PKG, cGMP-dependent protein
kinase; MLC, myosin light chain.
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NADPH: nicotinamide adenine dinucleotide phosphate
This reaction requires a number of cofactors, including flavin adenine dinucleotide (FAD)
and flavin mononucleotide (FMN) in the reductase domain for accepting and transferring
electrons from NADPH to heme iron, tetrahydrobiopterin (BH4) in the oxygenase domain,
and calmodulin/Ca2+ in the reductase domain (Alderton, W.K. et al. 2001). When either
BH4 or L-arginine substrate is limiting, NOS generates more superoxide rather than NO
(Dudzinski, D.M. et al. 2006). This condition is designated as NOS uncoupling.
eNOS activity control. Nitric oxide has a short half-life of less than 5 seconds in
vivo (Dudzinski, D.M. et al. 2006). Thus vascular NO bioavailability rigorously depends
on eNOS activity, which is regulated by multiple interconnected factors at different levels.
Vasoactive agonists, such as ACh and bradykinin, can increase intracellular calcium
levels to stabilize the binding of eNOS to calmodulin, which is required for maximal NO
synthesis. In addition, fluid shear stress, estrogen, insulin and inflammatory signals may
stimulate the catalytic activity of eNOS through PI3K/Akt-dependent phosphorylation.
eNOS can be phosphorylated at multiple sites, including two stimulatory sites: Ser1177
and Ser635, and two inhibitory sites: Thr495 and Ser116 (Dudzinski, D.M. et al. 2006).
The expression of eNOS enzyme is also regulated at transcriptional and
posttranscriptional levels (mRNA stability) by numerous factors, such as transforming
growth factor-β1 (TGF-β1) and oxidized low-density lipoprotein (LDL) (Searles, C.D.
2006). Major factors that regulate eNOS expression and/or enzyme activity are listed in
table I.
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Table I. Regulatory factors of eNOS expression and activity.
Regulatory factor

Regulatory mechanism

References

Acetylcholine ↑

Intracellular Ca2+

Dudzinski, D.M. et al. 2006

Bradykinin ↑

Intracellular Ca2+
Phosphorylation

Harris, M.B. et al. 2001

Estrogen ↑

Transcription
Intracellular Ca2+
Phosphorylation

Caulin-Glaser, T. et al. 1997
Searles, C.D. 2006
Chambliss, K.L. et al. 2002

Hydrogen peroxide ↑

Phosphorylation

Thomas, S.R. et al. 2002

Insulin ↑

Phosphorylation

Montagnani, M. et al. 2001

Laminar shear stress ↑

Transcription
Phosphorylation

Ziegler, T. et al. 1998
Fisslthaler, B. et al. 2000

Lysophosphatidylcholine ↑

Transcription

Zembowicz, A. et al. 1995

Statins (3-Hydroxy-3methylglutaryl coenzyme A
reductase inhibitors) ↑

mRNA stability

Searles, C.D. 2006

TGF-β1 ↑

Transcription

Inoue, N. et al. 1995

VEGF ↑

mRNA stability
Phosphorylation

Papapetropoulos, A. et al. 1997
Tai, S.C. et al. 2004
Bouloumie, A. et al. 1999

Hypoxia ↓↑

Transcription
mRNA stability
Protein
Phosphorylation
Ca2+

Dudzinski, D.M. et al. 2006

LPS↓

mRNA stability

Lu, J.L. et al. 1996

Oxidized LDL ↓

Transcription
mRNA stability

Hernandez-Perera, O. et al.
1998
Tai, S.C. et al. 2004
Liao, J.K. et al. 1995

Thrombin ↓

Protein
phosphorylation

Ming, X.F. et al. 2002

TNF-α ↓

Transcription
Yoshizumi, M. et al. 1993
mRNA stability
Anderson, H.D. et al. 2004
↑: increases eNOS expression or activity; ↓: decreases eNOS expression or activity
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NO and endothelial dysfunction. Endothelial dysfunction, manifested as
impaired endothelium-derived nitric oxide (EDNO) bioactivity, refers to a loss of normal
homeostatic functions of the endothelium, such as vasodilatation, inhibition of platelet
aggregation and leukocyte adhesion. Reactive oxygen species (ROS) are very reactive
and widely accepted as the major causal factor of endothelial dysfunction and
cardiovascular diseases, including hypertension and atherosclerosis. They are naturally
generated by normal metabolism of oxygen as a byproduct and serve as signaling
molecules. Extra ROS are cleared by antioxidant enzymes, such as superoxide dismutase
(SOD), catalase and glutathione peroxidase, to protect cells from their harmful effects:

Under pathological stimuli, excessive ROS are produced by various enzymatic systems,
such as xanthine oxidase, cytochrome p450 and NADPH oxidase, which overwhelm the
self-defense capacity of the antioxidant system. There is also an increase of eNOS
expression in diseased vascular endothelium, which produces superoxide instead of NO.
Under this condition, uncoupled eNOS transfers an electron from NADPH to oxygen,
rather than the substrate, L-arginine, resulting in the production of superoxide instead of
NO (Verhaar, M.C. et al. 2004). This eNOS uncoupling is primarily caused by reduced
bioavailability of its cofactor, BH4, through a mechanism of which BH4 is oxidized by
peroxynitrite generated from NO and ROS (Thomas, S.R. et al. 2008, Figure 4).
Impaired EDNO production plus other factors can further contribute to the loss of
endothelial function and development of cardiovascular diseases.
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Figure 4. Effect of reactive oxygen species on endothelium-derived nitric oxide (revised
from Thomas, S.R. et al. 2008). Under pathological stimuli, various enzymatic systems
produce tremendous amount of superoxide, which reacts with NO to generate
peroxynitrite. Accumulated peroxynitrite oxidizes BH4 to uncouple eNOS, therefore
produces ROS rather than NO and finally impairs the EDNO bioavailability to cause
endothelial dysfunction. eNOS, endothelial nitric oxide synthase; NO, nitric oxide;
ONOO-, peroxynitrite; BH4, tetrahydrobiopterin; BH2, dihydrobiopterin.
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NITRIC OXIDE AND CARDIOVASCULAR HOMEOSTASIS
NO has been generally accepted as a crucial factor in maintaining cardiovascular
homeostasis including both blood pressure and cardiovascular organ function.
Insufficient NO contributes to the development of hypertension and atherosclerosis
(Huang, P.L. 2000), while excessive NO is the major cause of life-threatening
hypotension in sepsis and anaphylactic shock (Cauwels, A. 2007).
NO and blood pressure regulation. Under physiological circumstances, vascular
NO can either basally relax vasculature or be produced to counteract elevated blood
pressure to maintain normotension, both of which are basically mediated by shear stress
(Smiesko, V. et al. 1985). However dysregulation of NO can profoundly affect blood
pressure to induce either hypertension or hypotension pathologically.
The role of NO in maintaining normal blood pressure has been demonstrated in
rat and mouse models which develop different degrees of hypertension with NOS
blockade (Arnal, J.F. et al. 1992; Duling, L.C. et al. 2006; Gardiner, S.M. et al. 1990;
Gardiner, S.M. et al. 1992; Linder, A.E. et al. 2005). The significance of eNOS in NO
mediated blood pressure regulation is also highlighted by enos gene knockout mice that
exhibit high blood pressure (Huang, P.L. 2000). In contrast, over expression of eNOS
induces hypotension in mice (Ohashi, Y. et al. 1998) and attenuates the high blood
pressure in both stroke-prone spontaneously hypertensive rats and two-kidney one-clip
hypertensive mice (Gava, A.L. et al. 2008; Miller, W.H. et al. 2005), suggesting a
potential role of eNOS as a target in hypertension treatment.
NO-dependent hypotension also exists in pathological conditions, including sepsis,
a serious medical condition characterized by a whole-body inflammatory state (Levy,
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M.M. et al. 2003), and anaphylaxis, a sudden and severe systemic allergic reaction in the
absence of allergy history. Both conditions have extremely high mortality. The
fundamental role of NO in the development of hypotension in inflammation-associated
shock has been demonstrated in a number of animal models, in which NOS inhibitors
prevent hypotension induced by lipopolysaccharide (LPS), tumor necrosis factor (TNF),
interleukin-1, 2 and sepsis (Kilbourn, R.G. et al. 1990a; Kilbourn, R.G. et al. 1990b;
Kilbourn, R.G. et al. 1992; Kilbourn, R.G. et al. 1994; Petros, A. et al. 1991;
Thiemermann, C. et al. 1990). In septic hypotension, NO is from eNOS and iNOS, as
well as other sources, such as plasma nitrite (Cauwels, A. 2007). eNOS-derived NO
seems to play both a pro-inflammatory role and an organ protective role, while iNOSderived NO primarily contributes to excessive vasodilation (Cauwels, A. 2007; Connelly,
L. et al. 2005). Therefore, iNOS selective inhibitors showed a better effect on septic
shock than nonselective NOS inhibitors (Cauwels, A. 2007). In anaphylactic shock,
eNOS-derived NO is the primary vasodilator, which is activated via the PI3K/Akt
pathway (Cauwels, A. et al. 2006).
NO and atherosclerosis. In addition to vascular tone and blood pressure
regulation, NO inhibits leukocyte-endothelial adhesion, vascular smooth muscle
proliferation and migration, and platelet aggregation, all of which are critical steps in
atherosclerosis development (De Caterina, R. et al. 1995; Garg, U.C. et al. 1989a; b;
Sarkar, R. et al. 1996). Atherosclerosis has been demonstrated to be either accelerated by
NO deprivation and enos gene knockout or attenuated by NO substrate supplementation
and enos gene over expression in a number of animal models (Candipan, R.C. et al. 1996;
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Chen, J. et al. 2001; Kauser, K. et al. 2000; Kuhlencordt, P.J. et al. 2001; van Haperen, R.
et al. 2002).
ARYL HYDROCARBON RECEPTOR
The aryl hydrocarbon receptor (AHR) is a transcription factor that belongs to the
basic helix-loop-helix/PER-ARNT-SIM family of DNA-binding proteins. AHR mRNA
is expressed in multiple human tissues, with the highest expression in placenta, relatively
high expression in lung, heart, pancreas and liver, and lowest expression in the kidney,
brain and skeletal muscle (Dolwick, K.M. et al. 1993). AHR is well characterized for its
role in mediating organismal responses to xenobiotics by inducing xenobiotic
metabolizing enzymes. Halogenated aromatic hydrocarbons (HAH), such as 2,3,7,8tetrachlorodibenzo-p-dioxin (TCDD) and polycyclic aromatic hydrocarbons (PAH), such
as benzo(a)pyrene are two major categories of environmental compounds that activate
AHR signaling. The induction of metabolic enzymes is considered an adaptive response
of the organism to its environment, which could decrease the potential toxicity of foreign
chemicals. Through evolution of multicellular organisms, the function of AHR in
environmental adaption has also been put to use in important physiological processes,
which will be emphasized in the following discussion.
AHR alleles and molecular structure. Four murine AHR alleles, AHRb-1, AHRb2

, AHRb-3 and AHRd, have been found and cloned from different inbred and wild mouse

strains (Poland, A. et al. 1990; Poland, A. et al. 1987; Poland, A. et al. 1994; Schmidt,
J.V. et al. 1996a). The AHRd receptor has a lower ligand binding affinity compared to
the AHRb-1 and AHRb-2 alleles (Poland, A. et al. 1994). The AHRb-1 allele encodes a
protein of 805 amino acids, the AHRb-2 and AHRd alleles encode proteins of 848 amino
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acids, and the AHRb-3 allele encodes a protein of 883 amino acids. All proteins of four
alleles contain a basic helix-loop-helix motif (bHLH), PER-ARNT-SIM (PAS) domains
and a transactivation domain (TAD), and their varied amino acids exist at the carboxyl
end (Schmidt, J.V. et al. 1996a, Figure 5). An Ala375→Val375 polymorphism is
responsible for the reduced ligand-binding affinity of AHRd receptor compared with
AHRb2 receptor in both rodents and humans (Ema, M. et al. 1994; Poland, A. et al. 1994).

AHR signaling pathway. Unliganded AHR forms a complex including two
copies of 90-kDa heat shock protein (HSP90), one X-associated protein (XAP), and one
p23 molecular chaperone protein in the cytoplasm (Carver, L.A. et al. 1998; Kazlauskas,
A. et al. 1999; Ma, Q. et al. 1997; Meyer, B.K. et al. 1998). After being activated by its
ligands, cytoplasmic AHR translocates into the nucleus, disassociates from the chaperone
complex, dimerizes with the aryl hydrocarbon receptor nuclear translocator (ARNT) and
transactivates target genes through binding to dioxin response elements (DRE) in
promoter regions (Figure 6). AHR target genes include Phase I and Phase II metabolic
enzymes, such as cytochrome P450 1A1 (CYP1A1), cytochrome P450 1B1 (CYP1B1),
NAD(P)H:quinone oxidoreductase I (NQO1) and aldehyde dehydrogenase 3
(ALHD3A1). In addition to the induction of these enzymes, AHR mediates the toxic
endpoints of HAH exposure, including epithelial hyperplasia, porphyria, liver damage,
thymic involution, cancer, teratogenicity, a severe wasting syndrome, and death (Gu, Y.Z.
et al. 2000).
Studies using AHR deficient cells and animals indicate the role of AHR in normal
physiological processes without the involvement of any known exogenous ligands,
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Figure 5. The molecular structure of aryl hydrocarbon receptor (revised from Schmidt, J.V. et al. 1996a). NLS, nuclear translocation
signal; bHLH, basic helix-loop-helix; PAS, PER-ARNT-SIM; TAD, transactivation domain.
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Figure 6. Aryl hydrocarbon receptor signaling pathway. Upon binding of ligand, AHR
complex in the cytoplasm translocates into the nucleus and releases AHR/ligand to
dimerize with ARNT. This heterodimer subsequently binds to the DRE in target genes to
activate transcription. AHR, aryl hydrocarbon receptor; hsp90, heat shock protein 90;
XAP, X associated protein; ARNT, aryl hydrocarbon receptor nuclear translocator; DRE,
dioxin response element: 5’-T/GNGCGTGA/C-3’, N stands for any nucleotide.
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including cell cycle regulation, apoptosis, matrix metabolism, vascular development and
cardiovascular physiology (Kung, T. et al. 2009; Lahvis, G.P. et al. 2005; Puga, A. et al.
2009). The intrinsic activity of AHR signaling has been suggested to be subject to the
regulation by either endogenous ligands or nonligand activators. Variety of candidate
endogenous ligands have been isolated from mammalian tissues, including indigo,
indirubin, 2-(1'H-indole-3'-carbonyl)-thiazole-4-carboxylic acid methyl ester, arachidonic
acid metabolites, such as lipoxin 4A and prostaglandin G2, and heme metabolites, such as
bilirubin (Adachi, J. et al. 2001; Henry, E.C. et al. 2006; Schaldach, C.M. et al. 1999;
Seidel, S.D. et al. 2001; Sinal, C.J. et al. 1997). Moreover, ligand independent activators,
such as shear stress and cAMP can also regulate endogeneous AHR activity and the
expression of AHR target genes. The role of shear stress in AHR activation was initially
demonstrated by the observation that shear stress can induce CYP1A1 expression in an
AHR dependent manner (Eskin, S.G. et al. 2004; Mufti, N.A. et al. 1995a; Mufti, N.A. et
al. 1995b). Afterwards, modified low-density lipoprotein (LDL) was identified as a
mediator involved in the activion of AHR by shear stress (McMillan, B.J. et al. 2007).
The second messenger cAMP also modulates AHR signaling in a ligand independent
manner, in which AHR translocates into nucleus and binds to DRE without dimerizing
with ARNT (Oesch-Bartlomowicz, B. et al. 2005). Stimulation with N6-O2′-dibutyrylcAMP, a membrane-permeating derivative of cAMP or forskolin, a potent activator of
adenylate cyclase, inhibits AHR-mediated response to TCDD in mouse hepatoma cells
(Oesch-Bartlomowicz, B. et al. 2005). Those studies provide ample evidence of
xenobiotic independent AHR signaling modulation that may perform more fundamental
roles in developmental and physiological events.
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Phenotype of AHR knockout mice. ahr gene knockout mice have become a
powerful tool in investigating the role of endogenous AHR in physiological and
developmental processes. In 1990s, AHR deficient mice were developed independently
in three labs, by either deleting exon 1 (Fernandez-Salguero, P. et al. 1995; Mimura, J. et
al. 1997) or exon 2 (Schmidt, J.V. et al. 1996b) of the gene. All three AHR null mice had
a mixed C57BL/6 ×129 background and displayed a slower growth rate within the first
few weeks after birth, TCDD resistance, failure of xenobiotic CYP1A1 and CYP1A2
induction, maintained but decreased fertility and liver pathology. One line had ~50%
neonatal mortality rate (Fernandez-Salguero, P. et al. 1995; Mimura, J. et al. 1997), but
this may have been dependent on the manner of gene deletion. The AHR knockout mice
exhibit a spectrum of hepatic defects, including portal fibrosis and a smaller liver. The
mechanism underlying the liver defect seems due to fetal hepatic necrosis caused by
compromised perfusion (Harstad, E.B. et al. 2006; Walisser, J.A. et al. 2004a), and
partially resulted from a patent ductus venosus in adulthood, which is mediated by loss of
AHR in endothelial cells specifically (Lahvis, G.P. et al. 2000; Walisser, J.A. et al. 2004a;
Walisser, J.A. et al. 2005). Furthermore, abnormal vascular structures have been reported
in liver, kidney and hyaloid of AHR knockout mice (Lahvis, G.P. et al. 2000). It was
originally reported that AHR knockout mice had an impaired immune system, which was
demonstrated by decreased accumulation of lymphocytes in the spleen and lymph nodes
(Fernandez-Salguero, P. et al. 1995). However, the role of endogenous AHR in immune
function is not well-understood and needs to be further elucidated. Aged AHR knockout
mice also develop multiple organ lesions including cardiac hypertrophy and fibrosis,
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portal and uterine vascular remodeling, gastric hyperplasia and epidermal pathology
(Fernandez-Salguero, P.M. et al. 1997).
ARYL HYDROCARBON RECEPTOR AND CARDIOVASCULAR
PHYSIOLOGY
In addition to mediating PAH induced cardiovascular toxicity, AHR also plays a
fundamental role in cardiovascular development and physiology, which has been
demonstrated using AHR deficient mouse model.
AHR in cardiac hypertrophy. AHR is required in vascular development and in
cardiovascular physiology. AHR deficient mice develop cardiac hypertrophy and fibrosis
in adulthood (Fernandez-Salguero, P.M. et al. 1997; Thackaberry, E.A. et al. 2002;
Vasquez, A. et al. 2003). The mechanism involved in the development of cardiac
hypertrophy in AHR null mice may have many factors. Early characterization of the
enlarged heart in AHR null mice suggested that enhanced VEGF expression may
contribute to the hypertrophy phenotype (Thackaberry, E.A. et al. 2002). In 2003,
Vasquez et al reported increased size of cardiomyocytes and an anatomic remodeling
without typical features of molecular remodeling, which was not consistent with
hypertrophic growth secondary to pressure or volume overload (Vasquez, A. et al. 2003).
This suggested an intrinsic role of AHR in cardiomyocyte size control. In the same year,
Lund et al. indicated that cardiac hypertrophy in AHR null mice was associated with high
systemic arterial blood pressure as well as increased circulating angiotensin II (Ang II)
and plasma ET-1 level (Lund, A.K. et al. 2003). This cardiac hypertrophic phenotype
was primarily mediated by elevated circulating ET-1, thus treatment with BQ-123, an
ETA receptor antagonist, significantly attenuated the phenotype as well as the mRNA
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expression of cardiac hypertrophy makers, atrial natriuretic factor (ANF) and β-myosin
heavy chain (β-MHC) (Lund, A.K. et al. 2006). All the research data above suggest that
endogenous AHR contributes to the development of cardiac hypertrophy.
AHR in blood pressure regulation. The role of the AHR agonist, TCDD, in
inducing high blood pressure has been demonstrated in both epidemiology studies and
research using mouse models, in which AHR mediated cytochrome P450 induction may
be involved (Dalton, T.P. et al. 2001; Kang, H.K. et al. 2006; Kim, J.S. et al. 2003; Kopf,
P.G. et al. 2008; Pesatori, A.C. et al. 1998).
Besides ligand activated AHR, endogenous AHR also contributes to blood
pressure regulation in addition to cardiovascular development mentioned above.
Anesthetized AHR null mice were first found hypotensive in the absence of a heart rate
difference at 8 months old (Vasquez, A. et al. 2003). They also reported a decreased
cardiac output caused by diminished stroke volume in 4 month old AHR knockout mice
(Vasquez, A. et al. 2003). This finding suggested a role of AHR in causing hypotension
by decreasing cardiac function. Later in the same year, Lund reported high blood
pressure in conscious AHR null mice, associated with elevated circulating Ang II and
ET-1 levels (Lund, A.K. et al. 2003). In this study, angiotensin converting enzyme
blockade by captopril attenuated, but did not normalize elevated arterial blood pressure.
Afterwards, ET-1 was identified as the primary factor causing high arterial blood
pressure in those AHR null mice (Lund, A.K. et al. 2006). Treatment with BQ-123, an
ETA receptor blocker, dramatically attenuated mean arterial blood pressure as well as
plasma Ang II levels in AHR null mice, suggesting increased Ang II as a secondary effect
of ET-1 elevation. Another group in Mexico City also reported elevated arterial blood
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pressure in AHR null mice, which was normalized by captopril treatment (VillalobosMolina, R. et al. 2008). Their model also suggested an increase of vascular α-1D
adrenoceptor expression that was involved in the hypertensive phenotype. Interestingly,
both groups reported hypertension in AHR null mice located at high altitude
(Albuquerque NM, 1620m; Mexico City, 2240m). A further investigation of blood
pressure in AHR null mice indicated that loss of endogenous AHR in mice led to
hypotension at sea level and hypertension at mild high altitude, which was caused by
different atmospheric oxygen levels (Lund, A.K. et al. 2008). These data suggested that a
more complicated mechanism is involved in the role of endogenous AHR in regulating
blood pressure, and needs to be further elucidated.
AHR in endothelial dysfunction. Previous research demonstrated that the AHR
plays a very important role in mediating the toxic effect of its agonists to produce
endothelial dysfunction and atherogenesis, which involves production of toxic
metabolites and ROS in endothelial cells, abnormal cell adhesion and invasion and
imbalance of cholesterol metabolism (Granberg, A.L. et al. 2000; Iwano, S. et al. 2005a;
Iwano, S. et al. 2005b; Knaapen, A.M. et al. 2007; Korashy, H.M. et al. 2006; Meng, D.
et al. 2009; Oesterling, E. et al. 2008; Toborek, M. et al. 1995).
Endogenous AHR has been found to play an indispensible role in vascular
development in multiple organs (Lahvis, G.P. et al. 2000). The altered systemic blood
pressure in AHR null mice was also reported to be associated with a change of circulating
ET-1 levels, which was thought to be generated by endothelial cells primarily (Lund, A.K.
et al. 2003). Those observations suggested that endogenous AHR may be involved in
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cardiovascular development as well as vascular physiology in the absence of exogenous
ligands.
AHR in circadian rhythms. The expression of AHR exhibits circadian oscillation
and may be involved in mediating xenobiotic-induced disruption of circadian rhythms,
which are observed in most physiological functions, such as metabolism, cell growth and
immune responses (Shimba, S. et al. 2009). The daily cycle of relative AHR and ARNT
protein expressions exhibit similar oscillation patterns in multiple organs of female
Sprague-Dawley rats, respectively (Richardson, V.M. et al. 1998). In mice, the mRNA
expression of AHR and its target gene, CYP1A1, also exhibit circadian changes in the
suprachiasmatic nucleus and liver (Mukai, M. et al. 2008). The circadian rhythms of
behavior and of the immune system can be disrupted by activation of AHR with TCDD
(Garrett, R.W. et al. 2006; Mukai, M. et al. 2008). These observations suggest a possible
cross-talk between AHR and circadian rhythm pathways.
RATIONALE FOR RESEARCH
Cardiovascular diseases have been the number one killer in the United States for
decades. Hypertension and atherosclerosis are two types of cardiovascular diseases that
systemically affect the whole cardiovascular system and dramatically contribute to the
etiology of other types of cardiovascular defects, such as coronary heart disease and
stroke. Extensive research has been conducted to investigate the role of AHR in
mediating PAH/HAH induced cardiovascular diseases. Furthermore, AHR itself has
been found to be involved in vascular development and cardiovascular homeostasis.
These findings indicate that AHR has great potential impact in the etiology of
cardiovascular diseases from both environmental and genetic perspectives.
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AHR knockout mice have served as a very useful tool in studying the intrinsic
developmental and physiological functions of AHR. AHR deficient mice develop
vascular defects and cardiac hypertrophy (Fernandez-Salguero, P.M. et al. 1997; Lahvis,
G.P. et al. 2000; Thackaberry, E.A. et al. 2002; Vasquez, A. et al. 2003). AHR null mice
are hypotensive at sea level, but hypertensive at a mild high altitude (Lund, A.K. et al.
2008; Lund, A.K. et al. 2003; Vasquez, A. et al. 2003; Villalobos-Molina, R. et al. 2008).
The hypertensive phenotype at high altitude seems to be caused by the lower oxygen
concentration at high altitude, and through the mechanism of increased circulating
endothelin-1, angiotensin II and vascular adrenoceptor levels (Lund, A.K. et al. 2008;
Villalobos-Molina, R. et al. 2008). This may suggest that endogenous AHR contributes
to blood pressure stability and leads to high blood pressure, thus loss of AHR causes
lower blood pressure at sea level, but high blood pressure at mild high altitude, which
may be due to an impaired blood pressure regulating mechanism.
Interestingly, after living for a few years at high altitude, our AHR null mice now
have a hypotensive phenotype, which mimics the blood pressure phenotype observed at
sea level. Additionally, the former proposed mediators of high blood pressure, including
high circulating Ang II and ET-1 levels, no longer occur in these animals. This suggests
that the AHR null mice in Albuquerque have physiologically adapted to the altitude and
exhibit a blood pressure phenotype consistent with sea level animals. Although the
mechanism underlying this hypotensive phenotype may differ from AHR null mice that
are never raised at high altitude, there is no doubt that AHR plays a central role in this
hypotensive phenotype. It is also very possible that these two types of hypotension
caused by AHR deficiency share the same mechanism regardless of the altitude.
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The long-term goal of this research is to elucidate the mechanism by which
endogenous AHR regulates blood pressure, and loss of AHR contributes to blood
pressure control. However, potential mechanisms that may mediate hypotension in AHR
null mice have not been explored in great detail. Nonetheless, a few papers indicated that
TGF-beta and VEGF are increased in AHR null mice (Chang, X. et al. 2007; Guo, J. et al.
2004; Ichihara, S. et al. 2007; Thackaberry, E.A. et al. 2002), both of which could
regulate the expression or activity of eNOS, thus vascular NO, a potent vasodilator.
Therefore, we hypothesize that AHR suppresses vascular eNOS in maintaining normal
arterial blood pressure, and thus loss of AHR decreases arterial blood pressure due to an
elevated vascular eNOS and increased NO bioavailability.
To test our hypothesis, we proposed the following specific aims:
I.

Determine the degree of NO-mediated vasodilation and vascular eNOS
expression in AHR knockout mice in vivo. The working hypothesis for this aim is
that AHR suppresses eNOS expression, thus AHR knockout mice exhibit an
increased eNOS expression and NO-mediated vasodilation.

II.

Determine the degree by which eNOS over expression contributes to the
hypotension of AHR knockout mice in vivo. The working hypothesis for this aim
is that over expressed eNOS mediates the hypotension in AHR knockout, thus
eNOS inhibition can normalize the blood pressure of AHR knockout mice to
control level.

III.

Determine the degree by which AHR signaling knockdown contributes to eNOS
expression in human endothelial cells in vitro. The working hypothesis for this
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aim is that endogenous AHR signaling suppresses eNOS expression, thus AHR
signaling knock down can increase eNOS expression in human endothelial cells.
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CHAPTER II
MATERIALS AND METHODS
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CHEMICALS AND REAGENTS
Prazosin hydrochloride, hexamethonium chloride, Nω-nitro-L-arginine (LNNA),
phenylephrine hydrochloride (PE), acetylcholine chloride (ACh), S-Nitroso-N-acetyl-DLpenicillamine (SNAP), o-phenanthroline, p-hydroxymercuribenzoic acid, pepstatin A and
bisbenzimide H 33258 were purchased from Sigma Aldrich (St. Louis, MO). RIPA
(radio immuno precipitation assay) lysis buffer was purchased from Santa Cruz
Biotechnology (Santa Cruz, CA). Endothelial cell basal medium-2 (EBM-2), endothelial
cell growth medium-2 (EGM-2) and fetal bovine serum were purchased from Lonza
(Switzerland). Lipofectamine 2000 and Opti-MEM media were purchased from
Invitrogen (Carlsbad, CA). Precision Plus Protein All Blue Standard was purchased from
Bio-Rad laboratories (Hercules, CA). Diaminofluorescein-2 Diacetate (DAF-2DA) was
purchased from Cell Technology (Mountain View, CA). TCDD was a generous gift from
Dr. Richard E. Peterson (University of Wisconsin-Madison).
ANIMALS
AHR knockout mice were originally obtained from Dr. Frank Gonzales (National Cancer
Institute) and have been maintained by the Animal Resource Facility at University of
New Mexico since 2000 (Albuquerque NM, altitude 1620 m). Mice were housed under
conditions of constant temperature (22 °C), humidity (20%), a 12-h light/dark cycle, and
fully provided with mouse chow and water. All animals have been backcrossed to
C57B16N for more than 10 generations. Heterozygous sibling mice were used for
breeding in order to generate wildtype, AHR heterozygous and AHR knockout mice.
Age matched wildtype and AHR knockout mice were used in all experiments. All animal
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protocols were approved by the University of New Mexico Animal Care and Use
Committee and were in accordance with NIH guidelines.
CELLS
Primary human aortic endothelial cells (HAECs) were purchased from Lonza and
cultured in EGM-2 media at 37 °C, 5% CO2 according to the endothelial cell system
instruction of use (Lonza). Usage of cells was restricted to passages 1 to 4.
BLOOD PRESSURE, HEART RATE AND ACTIVITY ASSESSMENT
PA-C20 pressure telemeters (Data Sciences International, St. Paul, MN) were
used to assess arterial blood pressure, heart rate and activity of mice. Mice were
subcutaneously injected with 0.1 mg/kg buprenorphine 30 min prior to surgery, and
anesthetized with inhaled isoflurane (5% induction followed by 2-2.5% maintenance).
The telemeter catheter was inserted into the left carotid artery to the aortic arch and the
transmitter was placed subcutaneously in the abdomen. Mice were allowed to recover for
at least 7 days prior to any data collection. Basal blood pressure including systolic,
diastolic, mean and pulse arterial blood pressure, heart rate and activity were collected for
1 week before any treatments. All parameters were collected for 10 s every 15 min
except when specifically noted. Mice were monitored for body weight twice per week,
implanted telemeter signal strength and pinched or occluded catheter (reduced pulsewave), and any data collected after appearance of those conditions were excluded from
analyses.
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DETERMINATION OF PLASMA ANGIOTENSIN II (ANG II)
Plasma sample preparation. Four month old wildtype and AHR knockout mice
were anesthetized with ketamine (80 mg/kg)/xylazine (4 mg/kg), and euthanized by
exsanguination. Blood samples were collected from the right ventricle with syringe
containing 15 uL EDTA (0.5 M, pH8). Blood samples were mixed with a protease
inhibitor cocktail immediately in collecting tubes. The inhibitor cocktail was a mixture
of solution A (1.25 M EDTA, 50×, 20 uL for 1 mL of blood) and solution B (132 mM
phenanthroline in DMSO, 36 mM pepstatine A in DMSO and 300 mM p-hydroxymercuribenzoic acid in 0.1 M potassium phosphate pH7.4 containing 1% 10 N NaOH,
mixed at 1:1:1 ratio, 100×, 10 uL for 1 mL of blood). Within 30 min, plasma was
separated from whole blood by centrifuging at 3,000 x g for 15 min at 4 °C. Plasma
samples were stored at -80 °C before measurement and were thawed only at the time of
analysis.
Ang II measurement. Ang II was extracted from 0.4 mL plasma using Strata
phenyl cartridges (Phenomenex, Torrance, CA). The extracted sample was reconstituted
using buffer provided in the enzyme immunoassay kit (Cayman, Ann Arbor, MI) and
Ang II levels were measured in duplicate. Ang II concentration was determined from a
standard curve.
DETERMINATION OF PLASMA ENDOTHELIN-1 (ET-1)
Plasma sample preparation. Four month old wildtype and AHR knockout mice
were anesthetized with ketamine (80 mg/kg)/xylazine (4 mg/kg), and euthanized by
exsanguination. Blood samples were collected from the right ventricle with syringe
containing 15 uL EDTA (0.5 M, pH8). Within 30 min, plasma was separated from whole
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blood by centrifuging at 3,000 x g for 15 min at 4 °C. Plasma samples were stored at 80 °C and thawed only at the time of analysis.
ET-1 measurement. ET-1 was extracted from 0.3 mL plasma by Strata C18-E
cartridges (Phenomenex). Extracted samples were reconstituted in the buffer provided in
the enzyme-linked immunosorbent assay (ELISA) kit (human ET-1QuantiGlo
chemiluminescent ELISA kit, R&D, Minneapolis, MN) and subjected to measurement in
duplicate. ET-1 concentration was calculated from a standard curve.
DETERMINATION OF URINARY NOREPINEPHRINE (NE)
24 hour urine collection. Wildtype and AHR knockout mice were placed into
metabolic mouse cages, one animal per cage, to collect urine for 72 hours. Mice housed
in cage had full access to food and water. The first 24 hours were used as an acclimation
period, and urine generated in this period was discarded. Then, 24-hour urine samples
were collected twice in the subsequent 48 hours separately. Cages were cleaned and
dried between two collections, while urine samples were kept on ice. The 24-hour urine
volumes were assessed and recorded as an average of two collections. Urine samples
were stored at -80 °C.
Urine NE measurement. Urine samples were diluted 10 times in assay buffer
and NE concentration was measured using NE EIA kit (Alpco Diagnostics, Salem, NH).
NE concentration in each plate well was calculated from standard curve.
PRAZOSIN TREATMENT
Three month old wildtype and AHR knockout mice were implanted with PA-C20
pressure telemeters (Data Sciences International) for blood pressure and heart rate
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assessment. After one week recovery and one week baseline data collection, prazosin (1
ug/g, 0.1 ug/uL in sterile water) was injected intraperitoneally into conscious animals.
Telemetry parameters, including blood pressure and heart rate, were recorded for 10 s
every min for 5 hours after injection.
HEXAMETHONIUM TREATMENT
Three month old wildtype and AHR knockout mice were implanted with PA-C20
pressure telemeters (Data Sciences International) for blood pressure and heart rate
assessment. After one week recovery, one week base line data collection, prazosin
administration and one week drug washout period, hexamethonium (30 ug/g, 3 ug/uL in
sterile water) was injected intraperitoneally into conscious animals. Telemetry
parameters, including blood pressure and heart rate, were recorded for 10 s every min for
5 hours after injection.
VASCULAR REACTIVITY ASSESSMENT
Physiologic saline solution preparation. Physiologic saline solution was
prepared as mixed dry powder (130 mM NaCl, 4.7 mM KCl, 1.18 mM KH2PO4, 1.17
mM MgSO4, 14.9 mM NaHCO3, 5.5 mM glucose). Before aorta isolation, the proper
amount of dry powder was dissolved in 2 L water and supplemented with 20 mL of
CaNa2 EDTA (2.6 mM) and 20 mL of CaCl2 (180 mM) to achieve final concentrations of
26 uM CaNa2 EDTA and 1.8 mM CaCl2. Physiologic saline solution was bubbled for 30
min with 6% CO2, 21% O2 balanced N2 gas, adjusted to pH 7.4 and kept on ice.
Aorta isolation and preparation. Four month old wildtype and AHR knockout
mice were anesthetized with ketamine (80 mg/kg)/xylazine (4 mg/kg), and euthanized by
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exsanguination. Aortas were carefully dissected and placed in ice cold physiologic saline
solution. Aortas were carefully trimmed of connective tissue and cut into 2-3 mm
segments under a microscope while in ice cold physiologic saline solution. To disrupt
the endothelial cell layer, a piece of metal wire was inserted into the lumen of the aortic
ring, and the wire and vessel rolled back and forth two times. The aortic ring was hung
on two metal hangers that were carefully placed through the lumen, and rings were
quickly placed in the tissue bath (Radnoti Glass Technology Inc., Monrovia, CA) with
the lower hanger attached to a fixed stage and the upper hanger attached to a calibrated
force transducer (Grass Technologies, West Warwick, RI). The tissue bath was filled
with 37°C physiologic saline solution and constantly bubbled with 6% CO2, 21% O2
balanced N2 gas. The vascular tension of aorta rings was brought up to 250 mg for 10
min, subsequently adjusted to 500 mg for 10 min, 1,000 mg for 10 min and 1,500 mg for
30 min before any experiments.
Aortic reactivity to KCl and PE ± LNNA preincubation. Aortic rings were
contracted with 10-5 M PE and then 40 mM KCl for 10 min followed with 30 min
washout after each treatment. Washout was performed every 10 min during the 30 min
period. First, a KCl dose response (2.5 mM, 5 mM, 10 mM, 20 mM, 30 mM, 40 mM, 50
mM, 60 mM, 70 mM, 80 mM) was performed followed by a 30 min washout. The dose
of KCl was increased every 5 min. After the KCl dose response, a PE dose response (109

M, 10-8.5 M, 10-8 M, 10-7.5 M, 10-7 M, 10-6.5 M, 10-6 M, 10-5.5 M, 10-5 M) was performed

followed by a 30 min washout. The dose of PE was increased every 5 min. Finally,
aortic rings were preincubated with 10-4 M LNNA for 30 min immediately followed by a
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PE dose response (10-9 M, 10-8.5 M, 10-8 M, 10-7.5 M, 10-7 M, 10-6.5 M, 10-6 M, 10-5.5 M,
10-5 M) with the dose of PE increased every 5 min.
Aortic reactivity to ACh and SNAP. The aortic response to ACh was assessed on
intact aortic rings, while the aortic response to SNAP was assessed on endotheliumdisrupted aortic rings cut from the same aorta. A PE dose response (10-8 M, 10-7 M, 10-6
M, 10-5 M) was performed on both intact and endothelium-disrupted aortic rings followed
by a 30 min washout with the dose of PE increased every 5 min. The disruption of the
endothelium was confirmed by a much greater contraction to PE, compared to
endothelium-intact aortic rings. Then aortic rings were contracted with 80 mM KCl for
10 min followed by a 30 min washout. Intact smooth muscle was evaluated by an equal
contraction of endothelium-disrupted aortic rings and intact aorta rings. Finally, aortic
rings were contracted with 10-5 M PE for 10 min and relaxed with10-5 M ACh for 10 min.
ACh was only added to intact rings but not endothelium-disrupted rings. After a 40 min
washout on all aortic rings, both intact and endothelium-disrupted aortic rings were
contracted with 10-6 M PE for 10 min. An ACh dose response (10-9 M, 10-8.5 M, 10-8 M,
10-7.5 M, 10-7 M, 10-6.5 M, 10-6 M, 10-5.5 M, 10-5 M) on intact aortic rings and a SNAP
dose response (10-9 M, 10-8.5 M, 10-8 M, 10-7.5 M, 10-7 M, 10-6.5 M, 10-6 M, 10-5.5 M, 10-5
M) on endothelium-disrupted aortic rings were performed. Doses were increased every 5
min in both experiments.
DETERMINATION OF eNOS PROTEIN IN MOUSE AORTAS
Sample preparation. Four month old wildtype and AHR knockout mice were
anesthetized with ketamine (80 mg/kg)/xylazine (4 mg/kg), and euthanized by
exsanguination. Aortas were carefully dissected and placed in ice cold physiologic saline
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solution. Aortas were carefully trimmed of connective tissues and cut into 2-3 mm
segments under the microscope in ice cold physiologic saline solution. Aortas were
frozen at -80 °C for later homogenization if necessary. Aortas were homogenized in ~ 40
uL of RIPA lysis buffer (Santa Cruz Biotechnology) using PowerGen 125 homogenizer
(Fisher Scientific, Pittsburgh, PA) for 2 min on ice. Then homogenized aortas were
frozen at -80 °C for ~15 min to freeze followed thawing on ice. Aortas were then
sonicated for 20 s, frozen at -80 °C, thawed on ice and centrifuged at 15,000 x g 4°C for
10 min. Supernatant was saved at -80 °C as whole cell lysate. Protein concentration of
aortic lysates was measured using Bio-Rad protein assay (Bio-Rad Laboratories).
Western blot. A 30 ug protein aliquot was mixed with 2 × loading buffer (100
mM pH6.8 Tris-HCl, 4% sodium dodecyl sulfate, 0.2% bromophenol blue, 20% glycerol,
200 mM dithiothreitol added before using) and denatured at 95 °C for 5 min. Denatured
samples were subjected to electrophoresis on 7.5% Tris-HCL polyacrylamide gel (BioRad Laboratories) at 150 V for ~1 hour in running buffer (25 mM Tris-base, 150 mM
glycine, 0.1% sodium dodecyl sulfate). Separated protein was transferred to
polyvinylidene fluoride (PVDF) membrane (Bio-Rad Laboratories) at 350 mA for ~1
hour in cold transfer buffer (20 mM Tris-base, 150 mM glycine, 20% methanol). The
PVDF membrane was then briefly washed with Tris-buffered saline with tween (TBST,
0.8% NaCl, 0.02% KCl, 0.3% Tris-base, 0.05% Tween-20, pH7.4) and blocked for 1
hour in 5% dry milk made with TBST on a rocker. The blocked membrane was cut into
two pieces based on target protein size, thoroughly washed with TBST and then
incubated with rabbit anti phospho-eNOS (Ser1177) antibody (1:1000, Catalogue No.
9571, Cell Signaling Technology, Danvers, MA) or goat anti-actin antibody (1:1000,
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Santa Cruz Biotechnology) at 4 °C on shaker overnight. On the second day, the
membrane was washed with TBST and incubated with horseradish peroxidase (HRP)
conjugated goat anti-rabbit IgG (Southern Biotech, Birmingham, AL) or HRP conjugated
donkey anti-goat IgG (Southern Biotech) for 1 hour at room temperature on a rocker.
Then the membrane was washed with TBST and developed for 10 min by adding ~1 mL
chemiluminescence reagent (Perkin-Elmer, Waltham, MA) under KODAK Image Station
4000MM digital imaging system (Perkin-Elmer).
The membrane was stripped with stripping buffer (7 M guanidine hydrochloride,
0.75% KCl, 0.38% glycine, 50 uM EDTA, 0.14% 2-mercaptoethanol, pH10) for 10 min
on shaker and washed thoroughly with TBST. Then the membrane was blocked for 1
hour in 5% dry milk and incubated with mouse anti-eNOS antibody (1:2000, Catalogue
No. 610296, BD Transduction Laboratories, San Jose, CA) at 4 °C on shaker overnight.
On the second day, the membrane was washed with TBST and incubated with HRPconjugated goat anti-mouse IgG (Southern Biotech) for 1 hour at room temperature on
shaker. Then the membrane was washed with TBST and developed for 10 min by adding
~1 mL chemiluminescence reagent (Perkin-Elmer) under KODAK Image Station
4000MM digital imaging system (Perkin-Elmer). Precision Plus Protein All Blue
Standard was used in estimating molecule size on all Western blots.
LNNA TREATMENT
Three month old wildtype and AHR knockout mice were implanted with PA-C20
pressure telemeters (Data Sciences International) for blood pressure and heart rate
assessment. After one week recovery and one week base line data collection, 250 mg/L
LNNA was administrated through the drinking water for two weeks and then followed
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with 500 mg/L LNNA in drinking water for one additional week. Mice were returned to
regular water for at least one week before sacrifice. During this entire treatment period,
mouse body weight, water consumption, and blood pressure were carefully monitored.
Telemetry parameters, including blood pressure and heart rate, were recorded for 10 s
every 15 min. The drinking water containing LNNA was prepared fresh and changed
every 3 days.
DETERMINATION OF URINARY NOx
24 hours urine collection. Wildtype and AHR knockout mice were placed into
metabolic mouse cages, one animal per cage, to perform a urine collection for 72 hours as
described above. Urine collections were performed either before starting LNNA
treatment or while the mice were being dosed with 500 mg/L LNNA in the drinking
water.
Urine nitrate/nitrite assessment. Urine samples were diluted 10 times in assay
buffer and total nitrate/nitrite concentration was measured by Griess assay using
Nitrate/Nitrite Colorimetric Assay Kit (Cayman). Total nitrate/nitrite concentration was
predicted from standard curve.
siRNA TRANSFECTION
HAECs were grown in regular EGM-2 media at 37 °C, 5% CO2 for cell expansion.
Twenty-four hours before siRNA transfection, HAECs were plated at ~70-80%
confluence in antibiotic-free EGM-2 media. The day 2, 50 nM ON-TARGETplus
SMARTpool siRNA targeting AHR (Table II, Dharmacon, Chicago, IL) or 50 nM
siGENOME RISC-Free Control siRNA (Dharmacon) were reconstituted in Opti-MEM
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Table II. ON-TARGETplus SMARTpool AHR siRNA.

Duplex ID

Sense sequences

Antisense sequence

J-004990-05

GCAAGUUAAUGGCAUGUUUUU

PAAACAUGCCAUUAACUUGCUU

J-004990-06

GAACUCAAGCUGUAUGGUAUU

PUACCAUACAGCUUGAGUUCUU

J-004990-07

GCACGAGAGGCUCAGGUUAUU

PUAACCUGAGCCUCUCGUGCUU

J-004990-08

GCAACAAGAUGAGUCUAUUUU

PAAUAGACUCAUCUUGUUGCUU
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media and used to transfect HAECs with Lipofactamine 2000 as a delivery system
according to the manufacturer’s protocol (Invitrogen). Twenty-four hours later,
antibiotic-free EGM-2 media containing both lipofactamine 2000 and siRNA were
removed, and fresh EGM-2 media were added. Forty-eight hours after transfection, total
RNA was isolated from cells with RNeasy Mini Kit (Qiagen, Gmbh, Germany).
mRNA EXPRESSION ASSESSMENT
RNA concentration measurement. RNA concentration was measured using
NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE)
using 1 uL of samples.
cDNA synthesis. cDNA was synthesized using iScript Select cDNA Synthesis
Kit (Bio-Rad Laboratories) with supplied random primers and 250 ng total RNA.
Primer efficiency assessment. PCR primers for human AHR, human eNOS and
mammalian 18s (Table III) were purchased from Sigma Aldrich. Primers were
thoroughly reconstituted with 100 uL DNase/RNase free water (Sigma Aldrich).
Concentrations of primers were measured using NanoDrop ND-1000 spectrophotometer
(NanoDrop Technologies). The optimal primer concentration was assessed by using 100
uM, 250 uM and 500 uM of sense and antisense primers in a 25 uL PCR reaction
containing 12.5 uL iQ SYBR Green Supermix (Bio-Rad Laboratories) and 0.5 uL cDNA.
The PCR reactions were started with a complete denaturation at 95 °C for 3 min;
followed by 40 amplification cycles containing a 30 s denaturation at 95 °C and a 1 min
annealing and extension at 60 °C. A melt curve was obtained for each sample at the end
of the last amplification cycle, using the following parameters: 84 cycles starting at 54 °C
and increasing 0.5 °C every 5 s. The primer concentration that generated the best melt
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curve was chosen as the optimal concentration and used in the subsequent primer
efficiency assessment.
A PCR amplification was performed using the same protocol as described above
with 25 uL system including 12.5 uL iQ SYBR Green Supermix, 2 uL of the chosen
concentration of primers and a series amount of cDNA: 0.125 uL, 0.25 uL, 0.5 uL, 1 uL,
2 uL. The CT values for the target gene determined from the PCR reaction were plotted
against the volume of cDNA and used to calculate primer efficiency, which was used in
the target gene assessment.
Target gene expression analyses. Expression level of AHR mRNA, eNOS
mRNA and 18s rRNA were quantitated by real time PCR amplification. PCR
amplifications were performed on a 25 uL mixture of 12.5 uL iQ SYBR Green Supermix,
0.5 uL of synthesized sample cDNA and 500 uM primers for AHR and eNOS or 250 uM
primers for 18s using iCycler PCR machine. The PCR reactions were started with a
thorough denaturation at 95 °C for 3 min; followed by 40 amplification cycles containing
a 30 s denaturation at 95 °C and a 1 min annealing and extension at 60 °C. A melt curve
was also obtained as described above. Samples were run in triplicate and CT (threshold
cycle) values of each run were averaged. Relative expression was calculated by
subtracting CT value of 18s rRNA from CT value of target gene as previously described
(Muller, P.Y. et al. 2002).
eNOS PROTEIN ASSESSMENT IN HAECS
HAECs were grown at 37 °C, 5% CO2 in EGM-2 media (Lonza). Cells were
transfected with either 50 nM ON-TARGETplus SMARTpool siRNA targeting AHR
(Dharmacon) or 50 nM siGENOME RISC-Free Control siRNA (Dharmacon). Forty
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eight hours after transfection, cells were trypsinized using 0.25% trypsin-EDTA
(Invitrogen) and centrifuged at 500 rpm for 5 min. Cell pellets were resuspended in
proper amount of RIPA lysis buffer (Santa Cruz Biotechnology) and homogenized for 30
s on ice using hand-held motorized pestles (Sigma) in 1.5 mL centrifuge tubes. Cells
were subjected to two freeze-thaw cycles at -80 °C and were centrifuged at 15,000 x g
4°C for 10 min. The supernatant was saved at -80 °C as whole cell lysate. Protein
concentration of cell lysates was measured using Bio-Rad protein assay (Bio-Rad
Laboratories). Total eNOS protein was assessed by western blot as described above.
Protein aliquots (50 µg) were used in western blot for each sample.
NO SYNTHESIS ASSESSMENT IN HAECS
siRNA transfection. HAECs were transfected with 50 nM ON-TARGETplus
SMARTpool siRNA targeting AHR (Dharmacon) or 50 nM siGENOME RISC-Free
Control siRNA (Dharmacon) as described above.
NO production assessment. After 48 hours, cell culture media was removed, and
cells were washed twice with 37 °C warm sterile Kreb Ringer (KR) buffer (20 mM
HEPES, 10 mM glucose, 127 mM NaCl, 5.5 mM KCl, 1 mM CaCl2, 2 mM MgSO4,
pH7.4). DAF-2DA (Cell Technology) was diluted 1:500 in KR buffer, and 400 uL of
diluted DAF-2DA was added to each well of the 24-well plate. KR buffer was added to
control siRNA transfected cells as a background control. HAECs were incubated at
37 °C, 5% CO2 in dark for 45 min to 1 hour. Then cells were washed thoroughly with
warm KR buffer for 3 times to get rid of extra DAF-2DA. Then, 0.5 mL of KR buffer
containing 10-6.5 M ACh was added to each well. Cells were incubated at 37 °C, 5% CO2
in dark for 10 min. Fluorescence was measured with an excitation wavelength of 488 nm
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Table III. Real time PCR primer sequences.

Gene

Sense primer

Antisense primer

Mammalian 18s

CGGAGGTTCGAAGACGATCAGATA

TTGGTTTCCCGGAAGCTGCC

Human AHR

GGCCGTGTCGATGTATCAGTG

GTACTGGATTGTACTGCATCTGAC

Human eNOS

TCTCCGCCTCGCTCATG

AGCCATACAGGATTGTCGCC

Human CYP1A1

CACATGCTGACCCTGGGAAAG

GGTGTGGAGCCAATTCGGATC

46

and an emission wavelength of 515 nm at an optimal gain using a GENios plate reader
(Tecan, Mannedorf, Switzerland).
Normalization to DNA content. After DAF-2DA fluorescence measurement,
cells in plate were frozen at -80 °C overnight. On the second day, the plate was thawed at
room temperature for at least two hours. Two volumes of high salt TNE buffer (10 mM
Tris-base, 2 M NaCl, 1 mM Na2-EDTA, pH7.4) containing 18 nM bisbenzimide H 33258
was added to each well and incubated at room temperature in the dark over night.
Fluorescence was measured with an excitation wavelength of 360 nm and emission
wavelength of 465 nm at a gain of 96 using a GENios plate reader (Tecan). All DAF2DA fluorescence values were normalized to DNA content. Plate wells without cells
were loaded with all reagents and used as a background control.
ASSESSMENT OF SECRETED FACTOR IN MEDIATING eNOS INDUCTION
IN HAECS
HAECs were grown at 37 °C, 5% CO2 in EGM-2 media (Lonza) to expand cell
population, and then cultured in EBM-2 media (Lonza) supplemented with only
antibiotics and 5% fetal bovine serum for experiment. HAECs were transfected with 50
nM ON-TARGETplus SMARTpool siRNA targeting AHR (Dharmacon) or 50 nM
siGENOME RISC-Free Control siRNA (Dharmacon) in EBM-2 media with only 5%
serum on day 1. On day 2, media was changed back to EBM-2 suplemented with both
antibiotics and 5% serum for transfected cells. On the same day, another set of HAEC
was transfected with the same manner as the first set of cells. On day 3, the media
collected from the first set of cells transfected with control siRNA or AHR siRNA were
transferred into the second set of cells transfected with AHR siRNA or control siRNA,
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respectively. RNA was isolated from the first set of cells on day 3, and RNA from the
second set of cells was isolated on day 4. eNOS and AHR mRNA expressions were
analyzed by real time PCR as described previously.
DETERMINE EFFECT OF AHR SIGNALING ON eNOS INDUCTION IN
HAECS
HAECs were grown at 37 °C, 5% CO2 in EGM-2 media (Lonza) for experiment.
Cells were tranfected with either 50 nM ON-TARGETplus SMARTpool siRNA targeting
AHR (Dharmacon) or 50 nM siGENOME RISC-Free Control siRNA (Dharmacon) on
day 1, and then treated with either 0.1% DMSO or 1 nM TCDD after 24 hours in each
siRNA treatment group respectively. 48 hours after transfection, RNA was isolated, and
eNOS, AHR and CYP1A1 mRNA expressions were analyzed by real time PCR as
described previously.
STATISTICAL ANALYSES
The data were expressed as mean ± SEM. Statistical analyses were performed
with Student’s t test, two-way analysis of variance (ANOVA), and two-way repeated
measures ANOVA as noted. A p < 0.05 was considered significant in all cases.
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CHAPTER III
HYPOTENSION AND ELEVATED ENDOTHELIAL NITRIC OXIDE
SYNTHASE IN ARYL HYDROCARBON RECEPTOR KNOCKOUT
MICE

49

SYSTEMIC BLOOD PRESSURE, HEART RATE AND LOCOMOTOR
ACTIVITY OF ARYL HYDROCARBON RECEPTOR KNOCKOUT MICE
Systemic arterial blood pressure. Systemic blood pressure was measured by
radiotelemetry 24 hours/day for 4 days before any treatments in conscious wildtype and
AHR knockout mice. AHR knockout mice had significantly lower mean arterial blood
pressure compared with wildtype animals (AHR+/+: 105.9 ± 0.8 mm Hg; AHR-/-: 89.3 ±
2.4 mm Hg, Figure 7A). Similarly, AHR knockout mice showed significantly lower
systolic (AHR+/+: 120.2 ± 0.9 mm Hg; AHR-/-: 101.3 ± 2.9 mm Hg), diastolic (AHR+/+:
91.4 ± 1.4 mm Hg; AHR-/-: 76.2 ± 1.8 mm Hg) and pulse (AHR+/+: 29.8 ± 1.4 mm Hg;
AHR-/-: 26.1 ± 1.1 mm Hg) pressures than those of wildtype animals (Figure 7B).
Heart rate. Heart rate was measured by radiotelemetry 24 hours/day for 4 days
before any treatments in conscious wildtype and AHR knockout mice. There was no
significant difference in heart rate of wildtype and AHR knockout mice (AHR+/+: 528 ±
12 bpm; AHR-/-: 548 ± 10 bpm, Figure 8).
Locomotor activity. Locomotor activity of animals was recorded by
radiotelemetry 24 hours/day for 4 days before any treatments in conscious wildtype and
AHR knockout mice. The 24 hour average locomotor activity of AHR knockout mice
was significantly greater than wildtype mice (AHR+/+: 4.6 ± 0.3 counts/min; AHR-/-: 7.7 ±
0.8 counts/min, Figure 9).
Circadian systemic blood pressure, heart rate and locomotor activity rhythms.
Systemic arterial blood pressures including mean, systolic, diastolic and pulse pressure,
heart rate and locomotor activity were averaged for light/dark period or hourly over a 24
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Figure 7. Systemic mean arterial blood pressure (A), systolic, diastolic and pulse arterial
blood pressure (B) of AHR+/+ and AHR-/- mice. AHR+/+: n=11; AHR-/-: n=12. The data
represent the mean ± SEM and were analyzed by Student’s t-test; *p < 0.05, compared to
AHR+/+.
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Figure 8. Heart rate of AHR+/+ and AHR-/- mice. AHR+/+, n=11; AHR-/-, n=12. The data
represent the mean ± SEM and were analyzed by Student’s t-test.
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Figure 9. Locomotor activity of AHR+/+ and AHR-/- mice. AHR+/+, n=11; AHR-/-, n=12.
The data represent the mean ± SEM and were analyzed by Student’s t-test; *p < 0.05,
compared to AHR+/+.
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hour period for 4 days. All animals showed light/dark rhythms in systemic blood
pressure, heart rate and locomotor activity. The ratio of dark (1800-0500) and light
(0600-1700) values were compared between wildtype and AHR knockout mice. There
was a significant difference only in the ratio of dark/light locomotor activity between
wildtype and AHR knockout mice, but not in the ratio of mean, systolic, diastolic and
pulse blood pressure and heart rate (Table IV). The dark/light locomotor activity ratio
was significantly greater in AHR knockout mice. However, the 24 hour circadian pattern
of systemic blood pressure, heart rate and activity were not identical between the two
genotypes. The mean, systolic and diastolic blood pressure of wildtype animals exhibited
the typical bimodal waveform with peak values evident early and late in the dark period
(Li, P. et al. 1998, Figure 10 A, B and C, open circle, peaks indicated with arrows). In
contrast, the blood pressure waveform of AHR knockout mice showed a single peak in
the dark period (Figure 10 A, B and C, solid circle, peak indicated with arrow), and
instead of increasing, the nocturnal high blood pressure fell precipitously at the end of
dark period. Pulse pressure did not exhibit an obvious circadian change during 24 hours
in both genotypes of mice, and was generally lower in AHR knockout mice than wildtype
mice at most time points (Figure 11A). Heart rate increased at nighttime in both groups,
and was significantly greater in AHR knockout mice than wildtype mice from 2300 to
0100 (Figure 11B). The locomotor activity of AHR knockout mice dramatically
increased and was significantly higher than wildtype mice during most of the time at
night (1800-0200 except 2100), which accounted for the difference of 24-hour locomotor
activity between two genotypes (Figure 11C).
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Table IV. Circadian analyses of systemic blood pressure, heart rate and locomotor activity of AHR+/+ and AHR-/- mice.

+/+

Light

Dark

Dark / Light

102.6 ± 0.7

109.2 ± 1.3

1.06 ± 0.01

p-value

0.161

Mean arterial pressure (mm Hg)
-/-

85.1 ± 1.9

93.4 ± 3.0

1.10 ± 0.02

+/+

116.7 ± 0.9

123.8 ± 1.1

1.06 ± 0.01
0.166

Systolic arterial pressure (mm Hg)
-/-

97.5 ± 2.4

106.2 ± 3.5

1.09 ± 0.02

+/+

88.3 ± 1.5

94.6 ± 1.3

1.07 ± 0.01

-/-

72.8 ± 1.4

80.7 ± 2.3

1.11 ± 0.02

+/+

504 ± 11

552 ± 14

1.10 ± 0.01

0.156

Diastolic arterial pressure (mm Hg)

0.101

Heart rate (bpm)
-/-

514 ± 7

580 ± 13

1.13 ± 0.02

+/+

3.2 ± 0.2

6.0 ± 0.4

1.93 ± 0.16

-/-

3.8 ± 0.4

11.7 ± 1.3

3.22 ± 0.35

0.003*

Locomotor activity (counts/min)

The data represent the mean ± SEM and were analyzed by Student’s t-test; *p < 0.05, compared to AHR+/+.
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Figure 10. Circadian patterns of mean (A), systolic (B) and diastolic (C) arterial blood
pressure of AHR+/+ and AHR-/- mice. AHR+/+, n=11; AHR-/-, n=12. The data represent
the mean ± SEM and were analyzed by two-way repeated measures ANOVA, using post
hoc Holm-Sidak comparisons; *p < 0.05, compared to AHR+/+ at the given time point.
Blood pressure peaks are indicated with arrows.
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Figure 11. Circadian patterns of arterial pulse pressure (A), heart rate (B) and locomotor
activity (C) of AHR+/+ and AHR-/- mice. AHR+/+, n=11; AHR-/-, n=12. The data
represent the mean ± SEM and were analyzed by two-way repeated measures ANOVA,
using post hoc Holm-Sidak comparisons; *p < 0.05, compared to AHR+/+ at the given
time point.
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PLASMA ANGIOTENSIN II OF ARYL HYDROCARBON RECEPTOR
KNOCKOUT MICE
In order to determine the contribution of renin-angiotensin system to the
hypotension in AHR knockout mice, circulating Ang II levels were measured using
plasma collected from 4 month old wildtype and AHR knockout mice. There was no
significant difference in plasma Ang II levels between the two genotypes (Figure 12).
PLASMA ENDOTHELIN-1 OF ARYL HYDROCARBON RECEPTOR
KNOCKOUT MICE
To determine the role of ET-1 in the hypotensive phenotype of AHR knockout
mice, plasma ET-1 were measured using plasma collected from 4 month old wildtype and
AHR knockout mice. There was no significant difference in plasma ET-1 levels between
the two genotypes (Figure 13).
AUTONOMIC NERVOUS SYSTEM CONTRIBUTION TO HYPOTENSION IN
ARYL HYDROCARBON RECEPTOR KNOCKOUT MICE
The autonomic nervous system, including sympathetic and parasympathetic
innervations, can be altered to cause blood pressure misregulation. Thus, to determine
the possible contribution of this system to the low blood pressure in AHR knockout mice,
we first indirectly assessed the sympathetic nerve activity by measuring excretion of
urinary norepinephrine, which is the primary postganglionic neurotransmitter of
sympathetic nerves. We also evaluated the role of the sympathetic α-adrenoceptor axis in
systemic blood pressure regulation by blocking the α-adrenoceptor with prazosin in both
genotypes of animals. Finally, we examined the effect of total autonomic nervous system
blockade on blood pressure control using a ganglionic blocker, hexamethonium.
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Figure 12. Plasma angiotensin II of AHR+/+ and AHR-/- mice. AHR+/+, n=6; AHR-/-, n=7.
The data represent the mean ± SEM and were analyzed by Student’s t-test.
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Figure 13. Plasma endothelin-1 of AHR+/+ and AHR-/- mice. AHR+/+, n=6; AHR-/-, n=7.
The data represent the mean ± SEM and were analyzed by Student’s t-test.
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Urinary norepinephrine. AHR knockout mice did not exhibit any differences in
urinary norepinephrine concentration (Figure 14A) or 24-hour urine production (Figure
14B) compared to wildtype animals.
α-adrenoceptor blockade. We examined the contribution of systemic αadrenoceptor expression in this blood pressure alteration by blocking α-adrenoceptor with
prazosin in our animals. AHR knockout mice did not show any difference in the change
of mean arterial blood pressure following prazosin injection, compared to wildtype mice
(Figure 15).
Ganglionic blockade. In order to identify the contribution of autonomic nervous
system, including both sympathetic and parasympathetic never, to the low blood pressure
of AHR knockout mice, we treated our animals with a ganglionic blocker,
hexamethonium. Blood pressure was expressed as a change from baseline pressure while
heart rate was expressed as intrinsic heart rate with ganglion blockade. AHR knockout
mice did not show any difference in the change of mean arterial blood pressure compared
with wildtype mice (Figure 16A). In this study, AHR knockout mice showed a
significantly greater basal heart rate than wild type (Figure 16B), which was different
from what we determined previously (Figure 8). In addition, AHR knockout mice
showed an elevated intrinsic heart rate following hexamethonium injection, compared to
wildtype mice.
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Figure 14. Urinary norepinephrine concentration (A) and 24 hour urine volume (B) of
AHR+/+ and AHR-/- mice. AHR+/+, n=5; AHR-/-, n=7. The data represent the mean ±
SEM and were analyzed by Student’s t-test.
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Figure 15. Effect of prazosin on mean arterial blood pressure change of AHR+/+ and
AHR-/- mice. Blood pressure was calculated by averaging readings for half hour 5 min
after injection, and expressed as a change from 2 hours average pressure collected before
injection. AHR+/+, n=6; AHR-/-, n=6. The data represent the mean ± SEM and were
analyzed by Student’s t-test.
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Figure 16. Effect of hexamethonium on mean arterial blood pressure (A) and heart rate
(B) of AHR+/+ and AHR-/- mice. Blood pressure and heart rate were calculated by
averaging readings for half hour 5 min after injection, and expressed as a change from 2
hours average pressure collected before injection (A) or 4 days baseline heart rate (B),
respectively. AHR+/+, n=6; AHR-/-, n=5. The data represent the mean ± SEM and were
analyzed by Student’s t-test (A) and two-way ANOVA, using post hoc Holm-Sidak
comparisons; *p < 0.05, compared to AHR+/+ (B).
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VASCULAR REACTIVITY OF ARYL HYDROCARBON RECEPTOR
KNOCKOUT MICE
Systemic vascular resistance (SVR) is one of the most important factors that
directly determine systemic arterial blood pressure. SVR is regulated by multiple factors,
including autonomic innervations, Ang II, ET-1 from endothelium and other local factors,
such as nitric oxide, prostacyclin and endothelium-derived hyperpolarizing factors. After
investigating the possible role of autonomic nervous system, as well as Ang II and ET-1
in contributing to the hypotension in our mouse model, we further examined the vascular
reactivity in respond to KCl, phenylephrine (PE) and exogenous NO donor, as well as the
basal and ACh-induced NO-mediated vasorelaxation.
Vascular response to KCl. Intact aortic rings from wildtype and AHR knockout
mice were stimulated with KCl in a dose dependent manner. We observed a significantly
greater response with high doses KCl in aortic rings from AHR knockout mice compared
to those from wildtype mice (Figure 17).
Vascular response to PE. To determine the vascular reactivity in response to
neural hormone stimuli in vitro, we stimulated intact aortic rings isolated from both
genotypes with PE and expressed the data as percentage of the maximal response to KCl.
AHR knockout mice exhibited a diminished, but not significant, response to PE (Figure
18A).
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Figure 17. KCl induced vasocontraction of aortic rings from AHR+/+ and AHR-/- mice.
AHR+/+, n=6; AHR-/-, n=6. The data represent the mean ± SEM and were analyzed by
two-way repeated measures ANOVA, using post hoc Holm-Sidak comparisons; *p <
0.05, compared to AHR+/+ at the given concentration.
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Constitutive NO derived basal vasodilation. In order to determine the basal
vasodilatory tone derived from constitutive NO expression, we preincubated intact aortic
rings with LNNA, a NOS inhibitor, and then conducted a PE dose response. Contraction
was expressed as a percentage of the maximal response to KCl. We observed a
significantly greater vasocontraction in response to high concentrations of PE in AHR
knockout mice in the presence of LNNA (Figure 18B).
We subtracted the contraction values to PE without LNNA preincubation from
those with LNNA preincubation at each PE concentration. The result was expressed as a
percentage of the maximal response to KCl. This result represents the degree of
vasocontraction that is constitutively blocked by endogenous NO. There was a
significantly greater degree of vasocontraction offset by constitutive NO in the aortas of
AHR knockout mice than in wildtype mice (Figure 18C), suggesting that AHR knockout
mice have significantly higher production of aortic NO than wildtype mice.
Vasorelaxation to ACh. As a neurotransmitter released from parasympathetic
nerve, ACh can bind to muscarinic receptors on endothelial cells to activate NO
production by eNOS through an intracellular calcium-mediated mechanism. To
determine the level of ACh-induced vasorelaxation in aortas from both genotypes of mice,
we precontracted the aortic rings with PE, and then stimulated them with a dosedependent increase in ACh. We found a significantly greater relaxation at high dose of
ACh (Figure 19A) and a significantly diminished vasocontraction to PE (Figure 19B) in
the aortic rings from AHR knockout mice, compared to wildtype mice. The
vasorelaxation is consistent with what we observed on basal NO-dependent vasodilation,
again suggesting a higher level of NO production in the aorta of AHR knockout mice.
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Figure 18. Vasocontraction to PE (A), LNNA + PE (B) and [(LNNA + PE) – PE] (C) of
aortic rings from AHR+/+ and AHR-/- mice. AHR+/+, n=6; AHR-/-, n=6. The contraction
was expressed as a percentage of the maximal response to KCl. The data represent the
mean ± SEM and were analyzed by two-way repeated measures ANOVA, using post hoc
Holm-Sidak comparisons; *p < 0.05, compared to AHR+/+ at the given concentration.
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Figure 19. ACh-induced vasorelaxation (A) and PE-induced vasocontraction (B) of
aortic rings from AHR+/+ and AHR-/- mice. AHR+/+, n=7; AHR-/-, n=6. The contraction
was expressed as a percentage of response to PE (A) or 80 mM KCl (B). The data
represent the mean ± SEM and were analyzed by two-way repeated measures ANOVA,
using post hoc Holm-Sidak comparisons; *p < 0.05, compared to AHR+/+ at the given
concentration (A) and Student’s t-test; *p < 0.05, compared to AHR+/+ (B).
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Vasorelaxation to exogenous NO. Nitric oxide produced by eNOS in endothelial
cells diffuses into vascular smooth muscle cells to induce vasorelaxation through multiple
mechanisms, such as sGC activation. Therefore, the sensitivity of the downstream
pathways to endothelium derived NO in smooth muscle cells may also affect
vasorelaxation. To determine the sensitivity of aortic vascular smooth muscle cells to
NO, we conducted a dose response to the exogenous NO donor, S-Nitroso-N-acetyl-DLpenicillamine (SNAP), on PE precontracted, endothelium-disrupted aortic rings from
both groups of animals. We detected a significantly greater sensitivity to exogenous NO
in aortic rings from AHR knockout mice, compared to those from wildtype mice (Figure
20A). The vasocontraction of aortic rings to PE was the same between two genotypes of
mice (Figure 20B).
ENDOTHELIAL NITRIC OXIDE SYNTHASE EXPRESSION IN AORTAS OF
ARYL HYDROCARBON RECEPTOR KNOCKOUT MICE
To determine the expression of aortic eNOS, we measured total eNOS protein in
isolated aortas from wildtype and AHR knockout mice. Since phosphorylation of serine
1177

in eNOS is a major mechanism of post-translational activation of this enzyme, we

also assessed serine 1177 phosphorylated eNOS expression. Both total eNOS and
phosphorylated eNOS protein expressions were dramatically increased (6 fold) in the
aorta of AHR knockout mice, compared to wildtype mice (Figure 21). However, the
ratio of phosphorylated eNOS to total eNOS in aortas from two groups of animals was
not different.
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Figure 20. SNAP-induced vasorelaxation (A) and PE-induced vasocontraction (B) of
endothelium-disrupted aortic rings from AHR+/+ and AHR-/- mice. AHR+/+, n=6; AHR-/-,
n=6. The contraction was expressed as a percentage of response to PE (A) or 80 mM
KCl (B). The data represent the mean ± SEM and were analyzed by two-way repeated
measures ANOVA, using post hoc Holm-Sidak comparisons; *p < 0.05, compared to
AHR+/+ at the given concentration (A) and Student’s t-test (B).
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Figure 21. Aortic total eNOS and phosphorylated eNOS protein expression of AHR+/+
and AHR-/- mice. n=3. The data represent the mean ± SEM and were analyzed by
Student’s t-test; *p < 0.05, compared to AHR+/+.
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EFFECT OF NITRIC OXIDE SYNTHASE BLOCKADE ON HYPOTENSION IN
ARYL HYDROCARBON RECEPTOR KNOCKOUT MICE
Due to the pivotal role of NO in regulating systemic vascular resistance, thus
systemic arterial blood pressure, we tested the hypothesis that hypotension is mediated by
elevated NO production in AHR knockout mice. We treated wildtype and AHR
knockout mice with NOS inhibitor, LNNA, in their drinking water, measured arterial
blood pressure and heart rate by radiotelemetry, and measured urinary NOx before and
during LNNA treatment.
Mean arterial pressure with LNNA treatment. Mean arterial blood pressure of
wildtype mice significantly increased with 250 mg/L LNNA treatment (12.7 ± 1.4 mm
Hg) and with 500 mg/L LNNA treatment (17.6 ± 3.8 mm Hg. Figure 22A). However,
500 mg/L LNNA did not further significantly increase blood pressure of wildtype mice
compared to 250 mg/L LNNA treatment. Blood pressure dropped to baseline levels after
LNNA treatment was stopped (Figure 22B). In contrast, in AHR knockout mice, mean
arterial blood pressure only significantly increased with 500 mg/L LNNA treatment (9.6
± 5.2 mm Hg. Figure 22A). The blood pressure peaked on day 2 of 250 mg/L LNNA
treatment, but this increase was not sustained and blood pressure fell back to baseline
levels by day 5 (Figure 22B). As with wildtype mice, blood pressure returned to baseline
levels after LNNA treatment was stopped.
Heart rate with LNNA treatment. Heart rate was not altered by LNNA treatment
in either AHR wildtype or knockout mice (Figure 23).
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Figure 22. Effect of LNNA on mean arterial blood pressure of AHR+/+ and AHR-/- mice.
AHR+/+, n=5; AHR-/-, n=6. The data represent the mean ± SEM and were analyzed by
two-way repeated measures ANOVA, using post hoc Holm-Sidak comparisons; *p <
0.05, compared to regular water in each genotype respectively (A), or compared to
AHR+/+ at the given time point (B).
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Figure 23. Effect of LNNA on heart rate of AHR+/+ and AHR-/- mice. AHR+/+, n=5;
AHR-/-, n=6. The data represent the mean ± SEM and were analyzed by two-way
repeated measures ANOVA.
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Urinary NOx . Urinary NOx levels, an indirect indicator of systemic NO
production, was significantly increased in AHR knockout mice about 2 fold, compared to
wildtype mice (Figure 24). The elevated urinary NOx in AHR knockout mice was
significantly attenuated and normalized to the same level as wildtype mice when being
treated with 500 mg/L LNNA (Figure 24). AHR knockout mice did not show a
difference in 24-hour urine production compared to wildtype animals (Figure 24B).
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Figure 24. Effect of LNNA on urinary NOx production of AHR+/+ and AHR-/- mice.
AHR+/+, n=5; AHR-/-, n=7. The data represent the mean ± SEM and were analyzed by
two-way ANOVA, using post hoc Holm-Sidak comparisons; *p < 0.05, compared to
untreated AHR+/+; #p < 0.05, compared to untreated AHR-/-.
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CHAPTER IV
ELEVATED ENDOTHELIAL NITRIC OXIDE SYNTHASE
EXPRESSION IN HUMAN AORTIC ENDOTHEIAL CELLS WITH
ARYL HYDROCARBON RECEPTOR KNOCKDOWN
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AHR SIGNALING INHIBITION WITH AHR siRNA
To determine the function of AHR siRNA in inhibiting AHR signaling, we
transfected HAECs with AHR siRNA, and then treated cells with TCDD. We assessed
the mRNA expression of AHR and CYP1A1, which is a downstream target gene of AHR.
AHR mRNA was significantly knocked down to ~15% of control by AHR siRNA, and a
75 fold induction of CYP1A1 mRNA by TCDD was significantly attenuated to 3-fold by
simultaneous AHR siRNA treatment, suggesting an effective AHR signaling blockade by
AHR siRNA (Figure 25).
eNOS mRNA EXPRESSION WITH AHR KNOCKDOWN
To determine the effect of AHR signaling blockade on eNOS mRNA expression
in vitro, we inhibited AHR signaling with siRNA and then analyzed eNOS mRNA in
HAECs. eNOS mRNA was significantly increased ~50% with AHR signaling
knockdown in HAECs (Figure 26).
eNOS PROTEIN EXPRESSION WITH AHR KNOCKDOWN
To determine the effect of AHR signaling blockade on eNOS protein expression
in vitro, we inhibited AHR signaling with siRNA and then analyzed eNOS protein by
western blot in HAECs. We did not detect any changes in eNOS protein with AHR
signaling knockdown in HAECs (Figure 27).
NO PRODUCTION WITH AHR KNOCKDOWN
In order to determine the activity of eNOS in producing NO with AHR signaling
blockade, we knocked down AHR signaling with siRNA, and then assessed NO
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Figure 25. Effect of AHR siRNA on AHR signaling. mRNA expression was analyzed
by real time PCR, and 18s rRNA was used as an internal control. n=3. The data
represent the mean ± SEM and were analyzed by Student’s t-test; *p < 0.05, compared to
control siRNA treatment; #p < 0.05, compared to TCDD treatment.
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Figure 26. Effect of AHR mRNA knockdown on eNOS mRNA expression. mRNA
expression was analyzed by real time PCR, and 18s rRNA was used as an internal control.
n=3. The data represent the mean ± SEM and were analyzed by Student’s t-test; *p <
0.05, compared to control siRNA treatment.
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Figure 27. Effect of AHR mRNA knockdown on eNOS protein expression. n=3. The
data represent the mean ± SEM and were analyzed by Student’s t-test.
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production with DAF-2DA fluorescent probe in presence and absence of ACh stimulation
in cultured HAECs. eNOS catalytic activity was stimulated with ACh in cultured
HAECs treated with control and AHR siRNA, and a significant higher level of NO
production was observed in AHR siRNA treated cells, compared to control siRNA
treatment (Figure 28). This suggests that ACh-stimulated eNOS activity is significantly
increased when AHR signaling is inhibited in HAECs in vitro.
EFFECT OF AHR KNOCKDOWN ON SECRETED FACTORS THAT CAN
MODULATE eNOS mRNA EXPRESSION
VEGF and TGF-β are two growth factors over expressed in AHR deficient mice
(Chang, X. et al. 2007; Guo, J. et al. 2004; Ichihara, S. et al. 2007; Thackaberry, E.A. et
al. 2002), and which can induce eNOS mRNA expression in cultured endothelial cells
(Bouloumie, A. et al. 1999; Inoue, N. et al. 1995). To test the hypothesis that AHR
signaling knockdown induces eNOS mRNA expression through increased secretion of
VEGF and/or TGF-β1 in endothelial cells, we performed a media exchange assay using
HAECs. Cell culture media collected from HAECs following treatment with AHR
siRNA failed to alter eNOS mRNA expression in cells treated with control siRNA
(Figure 29). Similarly, media from cells treated with control siRNA did not affect eNOS
mRNA expression induced by AHR knockdown (Figure 29). These data suggest that
secreted factors do not mediate the increase in eNOS mRNA expression observed
following AHR knockdown.
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Figure 28. Effect of AHR mRNA knockdown on ACh-stimulated NO production. n=4.
The data represent the mean ± SEM and were analyzed by two-way ANOVA, using post
hoc Holm-Sidak comparisons; *p < 0.05, compared to control siRNA treatment with
ACh stimulation; #p < 0.05, compared to AHR siRNA treatment without ACh
stimulation.
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Figure 29. Effect of media collected from HAECs treated with AHR siRNA or control
siRNA on eNOS mRNA expression. mRNA expression was analyzed by real time PCR,
and 18s rRNA was used as an internal control. n=3. The data represent the mean ± SEM
and were analyzed by Student’s t-test; *p < 0.05, compared to control siRNA treatment.
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REQUIREMENT FOR AHR-MEDIATED SIGNALING IN eNOS mRNA
EXPRESSION
AHR is a transcription factor that primarily mediates transcription of xenobiotic
metabolizing enzymes upon activation by exogenous ligands, such as TCDD. To
determine the effect of activating AHR signaling on eNOS mRNA expression, we
assessed eNOS and CYP1A1, an AHR target gene, mRNA expression following
treatment of HAECs with TCDD, AHR siRNA, or both. TCDD dramatically activated
AHR signaling as reflected by a ~75 fold induction of CYP1A1 mRNA, but did not alter
eNOS mRNA expression (Figure 30). As observed previously, eNOS mRNA was
significantly increased following AHR knockdown with siRNA. Interestingly, however,
TCDD treatment of cells in which AHR was knocked down by siRNA resulted in a 3 fold
increase in CYP1A1 mRNA expression and a normalization of eNOS mRNA expression
back to control level (Figure 30). The ability of TCDD to induce a small increase in
CYP1A1 mRNA indicates that a small amount of functional AHR is still present in
HAECs when treated with AHR siRNA. Further, these data suggest that a potent
stimulus of AHR signaling (i.e. TCDD) is sufficient to suppress eNOS mRNA expression,
suggesting that AHR activation is mediating the suppression of eNOS mRNA.
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Figure 30. Effects of AHR activation and knockdown on eNOS mRNA expression. n=3.
The data represent the mean ± SEM and were analyzed by Student’s t-test; *p < 0.05,
compared to control siRNA treatment; #p < 0.05, compared to AHR siRNA without
TCDD treatment.
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CHAPTER V
DISCUSSION
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SYSTEMIC ARTERIAL BLOOD PRESSURE OF AHR KNOCKOUT MICE
Our research demonstrates the presence of a hypotensive phenotype in congenic
AHR knockout mice at mild altitude, and an increased vascular NO bioavailability
caused by eNOS over expression, which does not appear to account for the hypotension
in these animals.
Previously, AHR knockout mice have been reported to be hypotensive at sea level
and hypertensive at mild altitude (Lund, A.K. et al. 2008; Lund, A.K. et al. 2003;
Vasquez, A. et al. 2003; Villalobos-Molina, R. et al. 2008). Vasquez et al. found that 4
month old AHR knockout mice developed significantly diminished stroke volume and
anesthetized 8 month old AHR knockout mice had significantly lower blood pressure
(Vasquez, A. et al. 2003). The AHR knockout mice used in this study were not congenic
with the control animals, thus the segregation of blood pressure quantitative trait loci
could influence the observations reported from these mice. After this study was
published, our laboratory reported a hypertensive phenotype in C57Bl/6N congenic AHR
knockout mice at mild altitude (Albuquerque NM, 1620 m) and hypotension in the same
animals when maintained at sea level (Lund, A.K. et al. 2008; Lund, A.K. et al. 2003).
Notably, the hypertension of AHR knockout mice at mild altitude was normalized within
2 weeks by exposure to the partial pressure of oxygen at sea level, revealing that blood
pressure of AHR knockout mice is sensitive to small changes in atmosphere oxygen.
After more than 5 years maintaining these AHR knockout mice at mild altitude
(Albuquerque NM, 1620 m), they appear to have acclimated to the levels of atmospheric
oxygen and are no longer hypertensive. Thus, we began new studies to assess systemic
arterial blood pressure using radiotelemetry on wildtype and AHR knockout mice. We
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found that AHR knockout mice now exhibit a significantly lower mean arterial blood
pressure, compared to wildtype animals (AHR+/+: 105.9 ± 0.8 mm Hg; AHR-/-: 89.3 ± 2.4
mm Hg), which is consistent with the blood pressure of these mice at sea level (Lund,
A.K. et al. 2008). In addition, previously reported high plasma Ang II and ET-1 levels
were now found to be normal. These data suggest that our AHR knockout mice have
adapted to mild altitude and exhibit a blood pressure phenotype consistent with sea level
animals. In order to determine the driving mechanism of hypotension in our AHR
knockout mice, we began by assessing the autonomic nervous system and vascular
resistance.
Autonomic nervous system. Blood pressure is continuously regulated by
autonomic nervous system, including sympathetic and parasympathetic innervation of the
heart and peripheral vasculature. The etiologies of neurogenic hypotension have been
extensively documented clinically (Guyton, A.C. and Hall, J.E. 2006; Bradley, J.G. et al.
2003). Thus, we first tested the hypothesis that decreased sympathetic stimulation of
blood pressure is responsible for the hypotension in AHR knockout mice. We examined
the activity of sympathetic nerve activity indirectly by measuring the excretion of its
functional neurotransmitter, norepinephrine, in urine. We found that urinary
norepinephrine was not altered, failing to support our hypothesis and suggesting that
sympathetic nerve activity is normal in AHR knockout mice.
To further assess the contribution of the sympathetic nervous system to blood
pressure regulation, we used pharmacological blockade of this pathway focusing first on
the primary receptor mediating catecholamine-induced vasoconstriction, the αadrenoceptor. Mice lacking α1D-adrenoceptor or all three α-adrenoceptors have been
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reported to develop systemic hypotension (Sanbe, A. et al. 2009; Tanoue, A. et al. 2002).
Furthermore, an alteration of vascular α1D-adrenoceptor expression has been reported in
AHR knockout mice, suggesting that this receptor may play a role in blood pressure
regulation in AHR knockout animals (Villalobos-Molina, R. et al. 2008). Thus, we
injected AHR knockout mice with the selective α1-adrenoceptor antagonist, prazosin, and
recorded blood pressure. We observed that blood pressure dropped an equivalent amount
in wildtype and AHR knockout mice following prazosin treatment, suggesting that the
regulation of vascular tone by sympathetic stimulation of α1-adrenoceptors is the same in
AHR knockout mice compared to wildtype mice, again failing to support our hypothesis.
Finally, we assessed the global contribution of the autonomic nervous system to blood
pressure control by treating mice with a ganglionic blocker, hexamethonium, which will
block pre-ganglionic sites of both the sympathetic and parasympathetic nervous system.
Again, blood pressure dropped equally in the wildtype and AHR knockout mice as did
heart rate (∆ heart rate: AHR+/+: 75 ± 11 bpm; AHR-/-: 68 ± 6 bpm).
Taken together, all these data disprove our hypothesis and suggest that the
autonomic nervous system is not likely involved in the hypotension of AHR knockout
mice.
Systemic vascular resistance. Systemic vascular resistance represents a critical
determinant of systemic arterial blood pressure which is regulated by circulating
hormones, such as Ang II, autonomic nervous innervation, and local factors, such as
endothelial-derived NO and ET-1. Since we have excluded Ang II, ET-1, and autonomic
nervous system in causing hypotension in AHR knockout mice, we next assessed
vascular reactivity and the presence of local dilatory factors that regulate vascular tone.
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In addition, TGF-beta and VEGF are increased in AHR null mice (Chang, X. et al. 2007;
Guo, J. et al. 2004; Ichihara, S. et al. 2007; Thackaberry, E.A. et al. 2002), both of which
could regulate the expression or activity of eNOS, the enzyme that catalyzes vascular NO
synthesis. We tested the hypothesis that AHR suppresses vascular eNOS in maintaining
normal arterial blood pressure, and thus loss of AHR decreases arterial blood pressure
due to an elevated vascular eNOS and increased NO bioavailability.
NO is a vasodilatory molecule that is generated either by basal or stimulated
eNOS to control vascular tone, and thus blood pressure. In order to determine the
contribution of NO to the control of vascular tone, we assessed NO-dependent
vasorelaxation, the vascular smooth muscle response to NO and eNOS expression in
aortas from our animals. While we did not observe a significant increase in the
vasoconstrictor response of aortic segments to the α-adrenoceptor agonist, PE, we did
observe that PE-mediated vasocontraction significantly increased following blockade of
eNOS activity with LNNA. Further, the degree of basal vasorelaxation mediated by local
NO was revealed by subtracting the PE-mediated vasocontraction in the absence of
LNNA from that in the presence of LNNA. This revealed that the contribution of local
NO to offset PE-mediated vasocontraction is significantly greater in AHR knockout mice
than controls. In addition to the increase in basal NO-mediated vasorelaxation, we found
an increase in the ACh-stimulated vasorelaxation in aortas of AHR knockout mice.
These vascular reactivity data suggest that simulated NO production is elevated in aortas
of AHR knockout mice. Moreover, we observed an enhanced vasorelaxation of
endothelium-disrupted aorta to exogenous NO donor, suggesting an amplified signaling
transduction downstream of NO in vascular smooth muscle cells of AHR knockout mice.
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To determine vascular eNOS expression and systemic NO production, eNOS
protein was assessed in isolated aortas and NOx was measured in urine samples. We
found a 6-fold elevation in total and phosphorylated (Ser1177) eNOS protein in aortas of
AHR knockout mice compared with wildtype mice. This is the first time that an
increased eNOS expression has been discovered in AHR knockout mice. The over
expressed eNOS was accompanied by an increased urinary NOx level in AHR knockout
mice, which suggests elevated functional eNOS rather than uncoupled enzyme.
Based on these data, we then hypothesized that pharmacological blockade of
eNOS would normalize blood pressure in AHR knockout mice to control levels. To test
our hypothesis, we treated wildtype and AHR knockout mice with LNNA, a nonselective
NOS blocker, in the drinking water. Interestingly, blood pressure in AHR wildtype and
knockout mice significantly increased on the first two days of treatment. However, while
the increase of blood pressure was sustained in the wildtype mice, the increase in blood
pressure in AHR knockout mice was only transient, returning to pre-treatment levels on
day 3. An increase in the dose of LNNA did cause a persistent increase in blood pressure
in AHR knockout mice, but it still failed to increase their blood pressure to control levels.
Further, measurement of urinary NOx confirmed that LNNA treatment effectively
reduced systemic NO to control levels in AHR knockout mice.
The role of NO derived from eNOS in blood pressure regulation has been
demonstrated using both pharmacological blockade and genetically modified mouse
models. Previous studies have demonstrated that C57Bl/6 mice treated with nonselective
NOS inhibitor, Nω-nitro-L-arginin-methylester (L-NAME), develop hypertension
(Mattson, D.L. et al. 2006; Van Vliet, B.N. et al. 2003). eNOS deficient mice also
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develop hypertension, while, in contrast, transgenic mice over expressing eNOS exhibit
low blood pressure and low systemic vascular resistance (Huang, P.L. 2000; Ohashi, Y.
et al. 1998). Over expression of eNOS also attenuates the high blood pressure in both the
stroke-prone spontaneously hypertensive rat and the two-kidney one-clip hypertensive
mouse (Gava, A.L. et al. 2008; Miller, W.H. et al. 2005). These data suggest a role of
eNOS-derived NO in attenuating blood pressure in both physiological and pathological
conditions. In addition, pharmacological blockade of NOS in C57Bl/6 mice with LNAME induces blood pressure to the same level as eNOS deficient mice, and L-NAME
treatment does not further alter blood pressure in eNOS knockout mice (Kojda, G. et al.
1999; Lemmer, B. et al. 2008; Van Vliet, B.N. et al. 2003), suggesting a dominant role of
eNOS-derived NO in blood pressure control.
Our AHR knockout mice exhibit a similar increase in vascular eNOS expression
and a similar degree of hypotension as previously reported in eNOS transgenic mice
(Ohashi, Y. et al. 1998; van Haperen, R. et al. 2002). However, AHR knockout mice
exhibit quite different vasodilatory responses to ACh and the endothelium-independent
NO donor, SNAP. Transgenic eNOS over expressing mice show blunted vascular
responses to ACh and an exogenous NO donor, which are caused primarily by
diminished sGC/PKG signaling manifested as a lower cGMP level upon NO stimulation
(Adlam, D. et al. 2007; Ohashi, Y. et al. 1998; van Deel, E.D. et al. 2007; Yamashita, T.
et al. 2000). In contrast, aortas from our AHR knockout mice exhibit significantly
increased vasodilatory responses to ACh stimulation and significantly greater sensitivity
to an endothelium-independent NO donor. Those data suggest that AHR knockout mice
exhibit a similar degree of blood pressure drop and endothelial eNOS expression
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compared with eNOS over expressing mice, but different NO signaling transduction in
vascular smooth muscle cells.
In vascular reactivity assessment, we observed that aortas from AHR knockout
mice exhibit a significantly increased vasocontraction response to PE following blockade
of eNOS activity with LNNA, which may suggest an elevation of α-adrenoceptor
expression in aortas. This is consistent with previous report of vascular α1Dadrenoceptor over expression in AHR knockout mice (Villalobos-Molina, R. et al. 2008).
In their experiment, intact aorta isolated from AHR knockout mice showed significant
greater response to PE. However this elevated responsiveness to PE in our AHR
knockout mice was only observed after LNNA incubation, which blocks the basal
vasodilatory effect of NO generated by basal eNOS. Obviously, the absence of greater
responsiveness of intact AHR negative aorta to PE is due to eNOS over expression in
aortic endothelium. However, the equivalent amount of blood pressure drop caused by
prazosin treatment suggests that this difference in α-adrenoceptor expression may be only
limited to aorta rather than the systemic vasculature. Moreover, we also observed a
significantly greater contraction of aortas from AHR knockout mice to potassium
stimulation. These data may suggest alterations in adrenoceptor expression/distribution
and depolarization machinery in vasculature of AHR knockout mice that needs to be
further elucidated.
Blockade of eNOS with 500 mg/L LNNA in our AHR knockout mice failed to
normalize blood pressure to the same level of wildtype mice. Previous studies have
shown that doses as low as ~ 100 mg/L L-NAME, a LNNA precursor, could completely
block basal eNOS activity in blood pressure regulation in C57Bl/6 mice and bring their
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blood pressure to the same level of eNOS knockout C57Bl/6 mice (Lemmer, B. et al.
2008). The mean arterial blood pressure of eNOS deficient C57Bl/6 mice has also been
reported as ~120 mm Hg measured by radiotelemetry (Van Vliet, B.N. et al. 2003),
which is consistent with what we observed in wildtype mice with LNNA treatment.
Moreover, 1g/L L-NAME in drinking water can normalize blood pressure of eNOS over
expression mice in two weeks (Ohashi, Y. et al. 1998). These data suggest that the dose
of LNNA we used was sufficient for complete eNOS inhibition in our wildtype mice;
however, we cannot exclude the possibility that 500 mg/L LNNA was not sufficient to
block over expressed eNOS in our AHR knockout mice. In addition, we cannot
accurately estimate the efficiency of 500 mg/L LNNA in blocking over expressed eNOS
in AHR knockout mice by analyzing urinary NOx excretion either. We observed that
urinary NOx failed to reflect a change in vascular NO production before and after LNNA
treatment in wildtype mice, suggesting a high background level of systemic NOx.
Although this result suggests that LNNA normalized urinary NOx in AHR knockout mice,
there may be a significantly higher residual vascular NO that cannot be detected by this
method. Therefore, a double knockout mouse lacking both AHR and eNOS would be
one approach to define the degree to which eNOS over expression mediates hypotension
of AHR knockout mice.
Another mechanism that may be involved in causing hypotension and accounting
for the resistance of AHR knockout mice to LNNA is the increased sensitivity of vascular
smooth muscle cells to NO. eNOS over expressing mice exhibit a blunted vascular
response to NO, which is mediated by diminished sGC/PKG signaling in smooth muscle
cells (Adlam, D. et al. 2007; Ohashi, Y. et al. 1998; van Deel, E.D. et al. 2007;
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Yamashita, T. et al. 2000). Interestingly, we detected an increased vasodilatory response
to an exogenous NO donor in aortas from AHR knockout mice. Although sGC is
regarded as the principal intracellular NO receptor in mediating vasorelaxation in
vascular smooth muscle cells, NO can also activate K+ channels in an sGC-independently
manner, leading to K+ efflux and membrane hyperpolarization, or increase cytosolic Ca2+
uptake by sarcoplasmic reticulum through its oxidative product, peroxynitrite (Cauwels,
A. 2007). No direct evidence has been reported to connect AHR and the NO downstream
pathways, however, we did observe increased aortic contraction to extracellular K+
stimulation, which may suggest an alteration of K+ channel in the vasculature of AHR
knockout mice. Taken together, these data suggest that NO downstream signaling
pathways could also be altered and contribute to the hypotension and resistance to NOS
blockade in AHR knockout mice.
Myogenic response is characterized as cell membrane depolarization and
consequently constriction of vascular smooth muscle in response to increases in
transmural pressure (Huang, A. et al. 2005). It is primarily dependent on vascular smooth
muscle and contributes to the regulation of basal vascular tone and organ perfusion
(Schubert, R. et al. 1999). NO has been found to profoundly inhibit myogenic response
(Just, A. et al. 2005; Skarsgard, P.L. et al. 2000), which may be mediated by the level of
20- hydroxyeicosatetraenoic acid (20-HETE) (Huang, A. et al. 2005). 20-HETE is
synthesized from arachidonic acid by CYP450/ω-hydroxylation (CYP4A) and can inhibit
K+ channel and membrane hyperpolarization in vascular smooth muscle cells. NO is a
factor that can inhibit the expression and function of CYP4A (Harder, D.R. et al. 1995),
and thus increased NO production can diminish 20-HETE production and activate K+
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channel in smooth muscle cells, resulting in hyperpolarization and attenuation of
myogenic tone. Therefore, attenuated myogenic response by eNOS-derived NO may also
be involved in the development of hypotension in AHR knockout mice.
Others factors in blood pressure regulation. Mean arterial blood pressure is
determined by cardiac output and systemic vascular resistance. We have examined the
roles of autonomic nervous system, circulating ET-1, Ang II and vascular NO in the
blood pressure regulation of our animals, but failed to identify the primary driving factors
of hypotension in AHR knockout mice. To systemically assess the factors that may be
involved in hypotension of AHR knockout mice, we need to determine the cardiac output
and total peripheral resistance of those mice. Previous research shows that AHR
knockout mice exhibit diminished stroke volume (Vasquez, A. et al. 2003), cardiac
hypertrophy (Fernandez-Salguero, P.M. et al. 1997; Lund, A.K. et al. 2003; Thackaberry,
E.A. et al. 2002; Vasquez, A. et al. 2003) and kidney hypertrophy and fibrosis (Lund,
A.K. et al. 2003). Consistently, we observed cardiac and renal hypertrophy in our AHR
knockout mice. The abnormality of the heart in AHR knockout mice may contribute to
the hypotension by decreasing cardiac contractility, and thus cardiac output, which needs
to be further investigated. The possible functional alteration in the kidney of AHR
knockout mice may also cause hypotension through a disruption of fluid balance, which
is the long term regulatory mechanism of blood pressure. Although the hematocrit of
AHR null mice was not different from that of wildtype mice (data not shown), suggesting
the same blood volume between two genotypes of mice, a direct assessment of blood
volume may also need to be conduct to determine the effect of blood volume on
hypotension of AHR null mice in future studies.
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Arterial pulse pressure. Arterial pulse pressure is the change of blood pressure
during systole and is determined by stoke volume and aortic compliance (Klabunde, R.E.
2004). Vascular compliance is described as the ability of a vessel to distend and increase
volume with increasing transmural pressure. We found a significantly lower pulse
pressure in our AHR knockout mice (AHR+/+: 29.8 ± 1.4; AHR-/-: 26.1 ± 1.1). According
to the factors that could affect pulse pressure, the AHR knockout mice may have a
smaller stroke volume or an increased vascular compliance or both. Smaller stroke
volume has been reported in non-congenic AHR knockout mice (Vasquez, A. et al. 2003).
Previous studies also have demonstrated that pulse pressure is increased in eNOS
deficient mice, eNOS over expression may mediate the beneficial effect of exercise
training on aortic stiffness in rats, and the eNOS polymorphism influences aortic stiffness
in human (Chen, W. et al. 2004; Maeda, S. et al. 2005; Van Vliet, B.N. et al. 2003).
These data suggest that decrease in cardiac output and eNOS over expression may be
involved in determining the low pulse pressure phenotype of AHR knockout mice.
eNOS EXPRESSION AND AHR SIGNALING IN ENDOTHELIAL CELLS
eNOS expression and activity are regulated by a number of factors at multiple
levels, including transcription, mRNA stability, protein phosphorylation and enzyme
cofactor availability. On the transcriptional level, eNOS can be transactivated by various
factors, such as TGF-β, laminar shear stress, H2O2 and estrogen (Inoue, N. et al. 1995
Chambliss, K.L. et al. 2002; Ziegler, T. et al. 1998). The mRNA level of eNOS is also
regulated at posttranscriptional level by factors such as VEGF, which stabilizes eNOS
mRNA (Bouloumie, A. et al. 1999).
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In our in vivo study, we observed an elevated vascular eNOS expression in the
aortas of AHR deficient mice, suggesting a significant role of AHR in regulating eNOS
expression in vasculature. In our in vitro study on human aortic endothelial cells, we
detected elevated eNOS mRNA and ACh-induced NO production when AHR protein
was depleted by siRNA. Previous studies have provided very limited evidence
connecting eNOS expression with AHR signaling. Elevated TGF-β, which could activate
eNOS mRNA transcription (Inoue, N. et al. 1995), has been found in liver, and in
fibroblast and smooth muscle cells of AHR knockout mice (Chang, X. et al. 2007; Guo, J.
et al. 2004; Zaher, H. et al. 1998). Additionally, VEGF is also increased in AHR
deficient mice (Ichihara, S. et al. 2007; Thackaberry, E.A. et al. 2002). Therefore we
tested the hypothesis that loss of AHR in HAECs increases eNOS mRNA by secreted
factors in an autocrine manner. However, culture media from HAECs that contain
secreted factors produced by AHR knockdown failed to induce eNOS mRNA expression,
suggesting the absence of autocrine pathway in eNOS induction. In contrast, our
experiments demonstrated that diminished endogenous AHR signaling is required for
eNOS induction, which could be abolished by AHR signaling activation through TCDD
treatment. However, AHR signaling activation by TCDD did not further suppress eNOS
mRNA level. This is consistent with a previous research on the role of endogenous AHR
in liver vascular development. AHR deficient mice develop patent ductus venosus after
birth (Lahvis, G.P. et al. 2000). The mice carrying the hypomorphic AHR allele also
develop patent ductus venosus, which could be rescued by TCDD treatment (Walisser,
J.A. et al. 2004a). In addition, nuclear translocation and DNA binding abilities of AHR
are both required in the closure of ductus venosus, suggesting a transactivation
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mechanism in endogenous AHR function (Bunger, M.K. et al. 2008; Bunger, M.K. et al.
2003). Taken together, these models suggest that the endogenous and exogenous ligandactivated AHR signaling may share the same signal transduction mechanism, in which
AHR translocation and DNA binding is required. Our model indicates a role for
endogenous activation of AHR in suppressing eNOS mRNA expression in endothelial
cells.
However, western blot failed to detect the difference in total eNOS protein
expression in HAECs treated with control and AHR siRNA, which was not consistent
with the 6 fold induction of eNOS protein in the aortas of AHR knockout mice. This
inconsistency could result from a number of factors. First, the degree of eNOS
suppression by AHR signaling may be greater in mice than in humans; therefore, AHR
signaling inhibition can cause greater induction of eNOS protein in mice than in humans.
In vivo, eNOS expression is maintained and regulated by blood flow shear stress, which
was not applied to the culture cells. The sustained exposure of endothelial cells to shear
stress amplifies both basal and inducible eNOS expression, and thus the increase of
eNOS protein expression caused by AHR blockade may also be amplified and easierto
detect in AHR knockout mice. Third, AHR signaling was completely blocked in AHR
knockout mice, but was only attenuated in HAECs, which may also account for the
different degree of eNOS protein induction between two models. Finally, factors
generated by smooth muscle cells or in circulation of AHR knockout mice may also
contribute to the eNOS protein over expression in vivo. In contrast, cultured cells were
not exposed to those factors and may not be subjected to an extensive regulation by AHR
signaling as in vivo.
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SIGNIFICANCE OF eNOS OVER EXPRESSION
Beyond the role in blood pressure control, eNOS derived NO is also involved in
other important functions, thus increased NO production by over expressed eNOS is
beneficial in various pathological conditions.
NO has been demonstrated to inhibit leukocyte-endothelial adhesion, vascular
smooth muscle proliferation and migration, and platelet aggregation, all of which are
critical steps in atherosclerosis development (De Caterina, R. et al. 1995; Garg, U.C. et al.
1989a; b; Sarkar, R. et al. 1996). The atherosclerosis development has been found to be
accelerated in apolipoprotein E/eNOS double-knockout mice, which is not dependent on
the hypertension of those mice (Chen, J. et al. 2001; Kuhlencordt, P.J. et al. 2001). In
contrast, atherogenesis process is dramatically attenuated by eNOS over expression in
mice (van Haperen, R. et al. 2002). These data indicate a protective role of eNOS
derived NO in atherosclerosis development.
eNOS derived NO is important in preserving cerebral blood flow under ischemia
conditions, such as stroke, which has been demonstrated by the observation that eNOS
knockout mice develop larger strokes after middle cerebral artery occlusion (Huang, Z. et
al. 1996). Myocardial reperfusion injury is another pathological condition in which over
expressed eNOS in cardiomyocyte may play protective role (Brunner, F. et al. 2003;
Elrod, J.W. et al. 2006).
Based on the spectrum of beneficial effects of eNOS derived NO in
cardiovascular deleterious conditions, elucidation of the role of AHR in suppressing
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eNOS expression will offer a novel and promising target in cardiovascular disease
treatment.
CIRCADIAN SYSTEMIC BLOOD PRESSURE, HEART RATE AND
LOCOMOTOR ACTIVITY RHYTHMS
Circadian rhythms are observed in most physiological functions, including
metabolism, cell growth and immune responses (Shimba, S. et al. 2009). The daily cycle
of relative AHR and ARNT protein expressions exhibit similar oscillation patterns in
multiple organs of female Sprague-Dawley rats, respectively (Richardson, V.M. et al.
1998). In mice, the mRNA expressions of AHR and its target gene, CYP1A1, also
exhibit circadian changes in suprachiasmatic nucleus and liver (Mukai, M. et al. 2008).
Circadian rhythms of behavior and immune system can also be disrupted by activation of
AHR with TCDD (Garrett, R.W. et al. 2006; Mukai, M. et al. 2008). These observations
suggest that endogenous AHR signaling may affect circadian rhythms of certain
physiological functions.
A circadian oscillation of blood pressure occurs by both humans and rodents. In
humans, blood pressure increases on awakening, decreases during sleep and peaks in
early morning, which is highly associated with an excessive incidence of cardiovascular
events (White, W.B. 2007). As a nocturnal species, mice exhibit higher blood pressure
and heart rate at nighttime rather than in the light period. Furthermore, the waveform of
their blood pressure is bimodal, with evident peak values early and late in the dark period
(Li, P. et al. 1999). Their heart rate generally peaks at dark onset and reaches its lowest
point in the middle of both the light and dark periods (Li, P. et al. 1999).
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Our data demonstrate for the first time an alteration in the circadian
haemodynamic and locomotor activity rhythms of AHR knockout mice. In AHR
knockout mice, the light/dark differences of arterial blood pressure and heart rate were
not significantly different from wildtype mice. However, there were differences in 24 hr
blood pressure and heart rate waveforms between the two genotypes. The blood pressure
of AHR knockout mice increases normally at the onset of the dark period; however,
blood pressure in AHR knockout mice drops precipitously at the end of dark period. This
blood pressure drop led to a shorter window of time during the dark cycle when blood
pressure is elevated in AHR knockout mice. Patients who lack the normal fall in blood
pressure at the onset of the sleep cycle (non-dippers) have been shown to have an
excessive incidence of cardiovascular events, including stroke and atherogenesis
(Routledge, F.S. et al. 2007; White, W.B. 2007). Therefore, a shorter non-dipping period
might be beneficial to the cardiovascular system of AHR knockout mice in addition to
their low blood pressure.
The heart rate of AHR knockout mice was significantly greater than wildtype
mice from 2300 to 0100 hours, when the locomotor activity of AHR knockout mice also
reached its maximal values. The higher heart rate in AHR knockout mice may be a result
of the higher locomoter activity during that time period, since a higher metabolic level
would be required in those animals and result in an increase in cardiac output.
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CHAPTER VI
CONCLUSIONS AND FUTURE DIRECTIONS
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SUMMARY
Previously, AHR knockout mice have been reported to be hypotensive at sea level
and hypertensive at mild altitude (Lund, A.K. et al. 2008; Lund, A.K. et al. 2003;
Vasquez, A. et al. 2003; Villalobos-Molina, R. et al. 2008). After more than 5 years
maintaining AHR knockout mice at mild altitude (Albuquerque NM, 1620 m), they
appear to have acclimated to mild altitude and become hypotensive. Therefore, the
research performed here is to understand the mechanism of AHR in blood pressure
regulation, or specifically loss of AHR in causing hypotension.
Our research demonstrates no changes of plasma Ang II and ET-1 level in AHR
knockout mice compared to wildtype mice, indicating a loss of prior reported driving
factors of hypertension in those animals at mild altitude (Lund, A.K. et al. 2008; Lund,
A.K. et al. 2003). In addition, we did not detect any alterations in the contribution of
autonomic nervous system to hypotension in AHR knockout mice. First of all, we
detected a normal sympathetic nerve activity in AHR knockout mice, which was reflected
by urinary norepinephrine level. Prazosin, a selective α1-adrenoceptor blocker, caused
the same degree of blood pressure drop in both genotypes, which excludes the possible
role of different systemic α1-adrenoceptor expression in mediating lower vascular tone,
thus hypotension in AHR knockout mice. Finally, ganglionic blocker, hexamethonium,
induced the same change of blood pressure and heart rate between both genotypes,
suggesting an equal contribution of autonomic nervous system to blood pressure.
The research also demonstrates a significantly elevated vascular eNOS expression
in AHR knockout mice. We found an increased NO-dependent basal vasorelaxation in
isolated aortas of AHR knockout mice, which was revealed by a significantly greater PE106

mediated vasocontraction offset. The ACh-dependent vasodilation of aortas was also
increased in AHR knockout mice. Additionally, we demonstrated a greater sensitivity of
vascular smooth muscle to exogenous NO-mediated vasorelaxation in AHR deficient
aortas, indicating an amplified NO downstream signaling transduction in vascular smooth
muscle cells, which may also contribute to the hypotension. eNOS over expression was
confirmed by a 6 fold elevation of Ser1177 phosphorylated and total eNOS protein in AHR
deficient mouse aortas, and a 2 fold increase of systemic urinary NOx production in AHR
knockout mice.
Previous research has extensively demonstrated that NO derived by eNOS can
cause hypotension or attenuate high blood pressure either in eNOS over expressing mice
(Gava, A.L. et al. 2008; Miller, W.H. et al. 2005; Ohashi, Y. et al. 1998) or under
pathological shock conditions (Cauwels, A. et al. 2006). Therefore we blocked systemic
NO production with a nonselective NOS inhibitor, LNNA, in both wildtype and AHR
knockout mice. However, this treatment did not normalize the blood pressure of AHR
knockout mice to control level. The measurement of urinary NOx indicated a
normalization of systemic NOx production in AHR knockout mice to control level in
wildtype mice, but failed to prove a complete inhibition of eNOS in AHR knockout mice.
Moreover, the amplified NO downstream signaling transduction in vascular smooth
muscle cells could be another factor involved in this resistance to LNNA in AHR
knockout mice.
In addition to low blood pressure, we revealed the first time an altered circadian
rhythm in the locomotor activity and cardiac parameters of AHR knockout mice. The
AHR knockout mice exhibit significantly higher locomotor activity than wildtype mice
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during nighttime, which may contribute to a significantly greater midnight heart rate in
those animals. They also lose the typical bimodal pattern of nighttime blood pressure and
exhibit a precipitous blood pressure drop at the end of nighttime period, which differs
from the 24 hour blood pressure pattern of wildtype mice. The data suggest an important
role of endogenous AHR in regulating behavioral and cardiac circadian rhythmicity in
mice.
Our research on human aortic endothelial cells in vitro suggests an inhibitory role
of endogenous AHR signaling in eNOS mRNA expression. Endogenous AHR signaling
blockade with siRNA increased eNOS mRNA and NO production level in HAECs. The
increase of mRNA with AHR signaling blockade was abolished by exogenous AHR
agonist, TCDD, treatment. However, AHR signaling activation by TCDD did not further
attenuate eNOS mRNA expression, which implicates exogenous ligand-independent role
of AHR in eNOS mRNA regulation.
In summary, we reveal the first time that endogenous AHR signaling plays a very
important role in regulating circadian blood pressure and locomotor activity rhythms and
vascular eNOS expression, a pivotal factor in vascular homeostasis. Although our initial
research has not fully demonstrated the function of over expressed eNOS in hypotension
of AHR deficient mice, it indicates a very promising future of the research on AHR in
cardiovascular physiology and disease treatment.
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CONCLUSION
Beyond mediation of adaptive and toxic responses to xenobiotics, the significant
role of endogenous AHR in embryonic development and adult physiology starts to attract
more attention and remains to be further investigated.
As an orphan receptor, no high-affinity endogenous ligand of AHR has been
identified to date (Beischlag, T.V. et al. 2008). Although a few candidate endogenous
AHR ligands have been isolated from mammalian tissues (Nguyen, L.P. et al. 2008), they
are inclined to establish an intrinsic environment that sustains the endogenous signaling
of AHR in an integrated manner, rather than activate AHR individually. This exogenous
ligand-independent AHR signaling plays a relatively subtle but crucial role in variety of
cellular, developmental and physiological processes. AHR deficient cells exhibit
aberration in cell cycle progression and apoptosis (Chang, X. et al. 2007; Wu, R. et al.
2007). AHR knockout mice develop patent ductus venosus, persistent hyaloid arteries
and abnormal kidney vasculature (Lahvis, G.P. et al. 2000). Loss of AHR in mice also
causes blood pressure alteration and instability (Lund, A.K. et al. 2008; Lund, A.K. et al.
2003; Vasquez, A. et al. 2003; Villalobos-Molina, R. et al. 2008). Our results
demonstrate hypotension, alteration of circadian blood pressure, heart rate and activity
rhythms in AHR knockout mice, and elevated eNOS expression in both AHR knockout
mice and cultured human endothelial cells with diminished endogenous AHR signaling.
All the data suggest that the role of endogenous AHR signaling is significant in blood
pressure regulation and vascular homeostasis and more complicated than its role in
mediating xenobiotic responses.
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Due to the absence of potent endogenous ligands, the knowledge related to the
function of endogenous AHR signaling is very limited. The role of endogenous AHR in
maintaining basal level CYP1A1 mRNA expression has been observed in human
endothelial cells (Zhang, N. et al. 2007). AHR deficient mice develop patent ductus
venosus after birth (Lahvis, G.P. et al. 2000). In this model, nuclear translocation and
DNA binding abilities of AHR are both required in normal liver vascular development,
and the mice carrying hypomorphic AHR or ARNT allele also develop patent ductus
venosus, which could be rescued by TCDD treatment (Bunger, M.K. et al. 2008; Bunger,
M.K. et al. 2003; Walisser, J.A. et al. 2004a; Walisser, J.A. et al. 2004b). The research
on the function of endogenous AHR in vascular development suggests that endogenous
AHR signaling may also function through a gene transactivation pattern similar to ligandactivated AHR signaling. Our observation of elevated eNOS expression in both AHR
knockout mice and AHR signaling diminished endothelial cells is consistent with
previous data on liver vasculature development, suggesting a resemblance of endogenous
signaling with xenobiotic activation of AHR. However, eNOS is fully suppressed by
constitutive AHR signaling, which is not further attenuated by TCDD treatment in
endothelial cells. These data suggest an exogenous ligand-independent role of AHR
signaling, which is not addressed in the patent ductus venosus model. Because TCDD
does not affect eNOS expression in endothelial cells, our model cannot be interpreted by
the theory of common factor competition either, in which the deprivation of shared
factors could be facilitated by TCDD treatment.
In conclusion, endogenous AHR plays an important role in blood pressure
regulation and vascular homeostasis. Our data indicate that AHR is involved in blood
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pressure control, and suppresses eNOS expression thus vascular production of NO, the
pivotal molecule in endothelial function. Therefore, therapeutic approaches that target
the connection of AHR and eNOS could be beneficial to patients with hypertension and
vascular diseases, such as atherosclerosis.
FUTURE DIRECTIONS
eNOS gene knockout. The result of LNNA treatment suggests that over
expressed eNOS may not be the primary driving factor of hypotension in AHR knockout
mice, however, we cannot completely exclude the possible role of over expressed eNOS
in blood pressure regulation in those animals. Therefore, a genetic deletion of eNOS
gene in AHR knockout mice is required to fully address the degree by which eNOS over
expression contributes to the hypotension of AHR knockout mice. Due to the elevated
sensitivity of vascular smooth muscle to NO in AHR knockout mice, we may hypothesize
that enos gene knockout out can causes greater blood pressure increase in AHR knockout
mice compared to wildtype mice, but cannot normalize the blood pressure to the same
level of eNOS deficient mice. In this case, the difference in the degree of blood pressure
elevation caused by eNOS deletion between wildtype and AHR knockout mice pressure
should indicate the contribution of eNOS over expression to the hypotension in AHR
knockout mice.
Signaling pathways downstream of NO. In contrast to the blunted vascular NO
responsiveness caused by diminished sGC/PKG signaling in eNOS over expressed
transgenic mice (van Deel, E.D. et al. 2007; Yamashita, T. et al. 2000), our vascular
reactivity assessment reveals a significantly more sensitive vasodilatory response to
exogenous NO in endothelium-disrupted aorta of AHR knockout mice, suggesting an
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amplified NO downstream signaling transduction in smooth muscle cells. This
downstream signal amplification may be caused by an increase of intracellular sGC
activity, which can be tested using 1H-(1,2,4)oxadiazolo(4,3-α)quinoxalin-1-one (ODQ),
a sGC inhibitor in AHR knockout mice aorta ex vivo. sGC inhibition by ODQ in
endothelium-disrupted aortas could abolished the different responses to NO if high sGC
activity is the mediator of vascular hypersensitivity to NO. Other mediators of NO
downstream signaling, such as BK potassium channel, may also be involved in this
hypersensitivity to NO in AHR deficient vasculature and can be further investigated
using vascular reactivity assay ex vivo.
Other vasodilators. In conduit vessels, endothelium-derived NO and PGI2 are the
predominant factors in causing vasodilation, while in small resistant vessels, EDHF tends
to play a greater role in regulating vascular tone (Scotland, R.S. et al. 2005). Previous
research on eNOS knockout mice indicates a compensatory role of EDHF in vasodilatory
response (Huang, A. et al. 2000; Waldron, G.J. et al. 1999). NO has been reported to
attenuate EDHF release (Bauersachs, J. et al. 1996), and in contrast eNOS expression
could be up-regulated by EDHF treatment in endothelial cells (Wang, H. et al. 2003).
Those data suggest a cross talk between eNOS pathway and EDHF signaling. Thus
EDHF production may also be altered in AHR knockout mice, which may contribute to
hypotension and need further investigation. Additionally, AHR signaling may suppress
the expression of bradykinin, another potent vasodilator (Nukaya, M. et al. 2001), thus
loss of AHR may cause bradykinin mediated hypotension in mice. Finally, our data
suggest alterations of vascular reactivity in response to KCl and PE in AHR deficient
mice, which may disrupt the homeostasis of vascular tone control. Further investigation
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on these pathways that are involved in blood pressure control in AHR knockout mice will
help us to elucidate the mechanism of hypotension in those animals.
Cell culture studies. Our in vitro results suggest that eNOS expression is
suppressed by endogenous AHR signaling, but is not further attenuated by ligand
activated AHR. Endogenous AHR signaling inhibition causes eNOS over expression in
HAECs, which could be abolished by activating the residual AHR with TCDD. The data
implicate that endogenous AHR signaling suppresses eNOS mRNA expression either
directly through a mechanism of transcriptional regulation or indirectly through
interaction with other intracellular pathways.
A number of transcription factors involved in different pathways usually
accumulate in promoter to regulate gene transcription, thus the transcription level of a
target gene depends on the integrated effect of those factors. A typical transcription
activator could also perform as a suppressor if its participation into the transcription
machinery interferes with the efficiency of the entire transcriptional complex. AHR is
well recognized as a transcription factor in mediating gene transcription through binding
to dioxin response element (DRE) in promoter. Previous research suggests that
inhibitory DRE (iDRE) which contains DRE core sequences (5’-GCGTG-3’) for AHR
binding may exhibit in the promoter of 17β-estradiol (E2) target genes and disrupt the
E2-mediated transactivation of these genes (Duan, R. et al. 1999; Gillesby, B.E. et al.
1997; Krishnan, V. et al. 1995; Porter, W. et al. 2001; Wang, F. et al. 2001). There are
two putative pentanucleotide core sequences of DRE (-168 to -164 and -739 to -735) in
the promoter of human eNOS gene, another target gene regulated by estrogen on
transcription level (Kleinert, H. et al. 1998; Zhang, R. et al. 1995). However, no research
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has demonstrated any inhibitory effects of activated AHR on eNOS induction by E2. Our
data suggest an inhibitory effect of endogenous AHR on basal eNOS mRNA expression,
which may involve a recruitment of AHR to eNOS promoter to disrupt constitutive
transcription activity of this gene. Therefore, we can hypothesize that endogenous AHR
suppresses eNOS transcription by interrupting constitutive activity of transcription
machinery, thus loss of endogenous AHR increases transcription of eNOS mRNA in
endothelial cells.
To test this hypothesis, we need to determine: 1) whether any mediating factors
are involved in eNOS mRNA suppression by AHR signaling; 2) whether the eNOS
mRNA suppression by AHR is on transcription level; 3) whether AHR binding in
promoter of eNOS is required for the transcription suppression.
To determine whether any mediating factors are involved in eNOS mRNA
suppression by AHR signaling, we can block protein synthesis after AHR knockdown
with cycloheximide. Inhibition of protein translation will not affect eNOS mRNA over
expression by AHR knockdown, and eNOS mRNA normalization by TCDD
simultaneous treatment if the hypothesis is correct.
To determine whether the eNOS mRNA suppression by AHR is on transcription
level, we can perform nuclear run on assay on cells treated with control or AHR siRNA.
Isolated nuclei will exhibit a higher transcription rate of eNOS gene with AHR siRNA
knockdown if our hypothesis is true.
To determine whether AHR binding in promoter of eNOS is required for the
transcription suppression, we will transfect cells with eNOS promoter-driving luciferase
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reporter containing intact or mutated putative iDRE in promoter. The difference in
luciferase activity of different reporters with and without AHR siRNA treatment will
indicate the role of DNA binding in transcription suppression.
Pharmaceutical therapy. As a regulator of blood pressure and a suppressor of
eNOS gene, AHR represents a potential target of pharmaceutical drugs in hypertension
and vascular diseases treatment. Drugs that antagonize AHR may be able to reduce high
blood pressure and increase vascular NO production in patients with hypertension and
vascular diseases. Our research also demonstrated an enhanced vascular response to PE
in AHR heterozygous mice, which exhibit normal blood pressure, suggesting a greater
contribution of vasoconstrictor in vascular tone control and maintaining blood pressure
with attenuated AHR signaling. The normal blood pressure of AHR heterozygous mice
may be caused by a combined effect of eNOS over expression and increase of
vasoconstrictor mediated vascular resistance. Since AHR heterozygous mice resemble
the condition of AHR antagonist treatment, simultaneous administration of AHR
antagonists and other drugs that target vasoconstrictor pathway may improve the
treatment of hypertension by decreasing blood pressure more sufficiently.
Gene therapy. Our initial research on the role of endogenous AHR on eNOS
expression also offers a potential target for gene therapy of high blood pressure and other
vascular diseases. As an activator of xenobiotic metabolizing enzyme transcription, AHR
may not represent an ideal target of genetic modification. If our hypothesis above is true,
which means AHR suppresses eNOS expression through binding to its promoter, the
binding site of AHR in eNOS promoter could be a perfect target for gene therapy. Low
affinity sequence for AHR could be inserted into this region to substitute the iDRE and
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eliminate the suppression effect of AHR. The expression level of eNOS could be
controlled by delivering sequences with different AHR binding affinity.
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CHAPTER VII
APPENDIX
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ONE ALLELE OF AHR IS SUFFICIENT IN MAINTAINING NORMAL BLOOD
PRESSURE AND VASCULAR eNOS EXPRESSION
Hypothesis. One allele of AHR is sufficient in maintaining normal blood
pressure and vascular eNOS expression, thus AHR heterozygous mice exhibit normal
blood pressure, vascular constitutive NO dependent vasodilation and eNOS expression.
Methods. Systemic arterial blood pressure and heart rate of AHR+/- mice were
measured as previously described. Aortic reactivity to PE ± LNNA was assessed on
AHR+/- aortas as previously described. Aortic eNOS protein expression was assessed by
western blot as previously described.
Results. Systemic mean arterial blood pressure and heart rate were measured by
radiotelemetry 24 hours/day for 4 days in conscious wildtype and AHR heterozygous
mice. AHR heterozygous mice exhibited the same mean arterial blood pressure (AHR+/+:
105.9 ± 0.8 mm Hg; AHR+/-: 107.7 ± 1.7 mm Hg, Figure 31A) and significantly greater
heart rate (AHR+/+: 528 ± 12 bpm; AHR+/-: 573 ± 9 bpm, Figure 31B) compared with
wildtype animals.
AHR heterozygous mice exhibited a significantly greater vasocontraction in
response to high concentrations of PE either with or without LNNA incubation compared
with wildtype animals (Figure 32A and B). In addition, the LNNA incubated aortas from
AHR heterozygous exhibited a significantly greater response to as low as 10-7.5 M PE
(Figure 32B). We subtracted the contraction values to PE without LNNA preincubation
from that with LNNA preincubation at each PE concentration. This result represents the
degree of vasocontraction that is constitutively blocked by endogenous NO. There was a
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significantly greater degree of vasocontraction offset by constitutive NO in the aortas of
AHR heterozygous mice than in wildtype aortas only at medium PE concentrations
(Figure 32C).
Total eNOS protein expression was not altered in the aortas of AHR heterozygous
mice, compared to wildtype mice (Figure 33).
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Figure 31. Systemic mean arterial blood pressure (A) and heart rate (B) of AHR+/+ and
AHR+/- mice. AHR+/+: n=11; AHR+/-: n=6. The data represent the mean ± SEM and
were analyzed by Student’s t-test; *p < 0.05, compared to AHR+/+.
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Figure 32. Vasocontraction to PE (A), LNNA + PE (B) and [(LNNA + PE) – PE] (C) of
aortic rings from AHR+/+ and AHR+/- mice. AHR+/+, n=6; AHR+/-, n=6. The data
represent the mean ± SEM and were analyzed by two-way repeated measures ANOVA,
using post hoc Holm-Sidak comparisons; *p < 0.05, compared to AHR+/+ at the given
concentration.
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Figure 33. Aortic total eNOS protein expression of AHR+/+ and AHR+/- mice. AHR+/+,
n=4; AHR+/-, n=8. The data represent the mean ± SEM and were analyzed by Student’s
t-test.
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